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 “ Om het losschieten van een knoop te voorkomen, heb je frictie nodig, en om 
frictie te doen ontstaan moet er enigerlei druk zijn. Deze druk, in samenhang met 
de plek in de knoop waar die ontstaat, heet de kneep. De betrouwbaarheid van 
een knoop lijkt enkel en alleen af te hangen van de kneep” 
 
Uit: the Ashley book of knots 
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Atherosclerotic disease is the leading cause of death in Western society. 
Established risk factors as hypercholesterolaemia, hypertension, diabetes 
mellitus and smoking only explain a part of the number of patients with 
cardiovascular disease. More recently, hyperhomocysteinemia has also been 
considered as an additional risk factor for vascular disease[1,2] .  
Patients with severe hyperhomocysteinemia or classical homocystinuria caused 
by a deficiency in cystathionine β-synthase, a rare inborn error of metabolism, 
suffer from serious vascular disease[3]. Also, a blockade of homocysteine 
remethylation caused by defects of methylenetetrahydrofolate reductase or 
methionine synthase activities can lead to very high levels of plasma 
homocysteine which results in a high risk of arterial and venous vascular 
disease[4]. This observation has brought up the hypothesis that homocysteine is 
toxic to the vascular wall and that mild hyperhomocysteinemia is a possible risk 
factor for coronary artery disease [5]. Over the past twenty years retrospective 
and prospective studies have demonstrated an association between 
hyperhomocysteinemia and arterial vascular disease[6]. The relationship between 
homocysteine and vascular disease is based on: 
a) the observations of premature vascular disease in patients with 
homocystinuria  
b) the relationship between plasma homocysteine and both clinical 
vascular disease as well as preclinical atherosclerotic disease 
c) the relationship between homocystinuria in children and premature 
vascular disease in their parents or relatives 
d) improvement of cardiovascular disease or surrogate endpoints after 
homocysteine lowering therapy.  
However it still remains unclear whether elevated homocysteine levels itself are 
causally related to the increased cardiovascular risk or whether homocysteine is 
just a marker of the process involved in atherosclerotic disease[7]. 
 
Evidence is accumulating that elevated homocysteine causes endothelial 
dysfunction but the mechanisms responsible for endothelial dysfunction in 
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hyperhomocysteinemia are poorly understood[8]. Several investigators have 
shown that homocysteine reduces the bioavailability of NO and enhances smooth 
muscle cell proliferation, both of which are important markers of athero-
thrombotic disease [8]. Recently it was hypothesized that hyperhomocysteinemia 
may stimulate the formation of asymmetrical dimethylarginine, an endogenous 
inhibitor of NO synthase[9] . The relationship between hyperhomocysteinemia 
and endothelium-derived hyperpolarizing factor is less clear.  
A meta-analysis of 12 studies revealed that folic acid lowered total plasma 
homocysteine levels by 25%[10].  Addition of vitamin B12 led to a further 
reduction of 7%.  Vitamin B6 did not lower fasting homocysteine levels but 
uncontrolled studies have shown that post-load homocysteine levels were 
reduced  by 21% to 42 % [10,11]. 
 
Aim of this thesis: 
This thesis focuses on the relationship between homocysteine and coronary 
artery disease with emphasis on coronary endothelial function and progression of 
atherosclerosis. Secondly we investigated the relationship between genetic 
determinants of hyperhomocysteinemia focusing on possible optimal therapeutic 
strategies. 
With regard to the relationship of homocysteine and coronary artery disease, the 
following questions were addressed: 
1) Is hyperhomocysteinemia related to the extent and progression of 
atherosclerosis in coronary vessels? 
2) Is hyperhomocysteinemia associated with coronary endothelial 
function? 
3) Can homocysteine-lowering therapy in hyperhomocysteinemic patients 
improve coronary endothelial function? 
4) Can homocysteine-lowering therapy in normo-homocysteinemic 
patients improve coronary endothelial function? 
5) What is the optimal treatment regime with regard to homocysteine-
lowering? 
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With regard to genetic determinants of hyperhomocysteinemia the following 
questions were raised: 
1) Is the common thermolabile mutation in the MTHFR gene, 677 C→T 
associated with elevated plasma homocysteine and coronary artery 
disease? 
2) Concerning patients with this mutation, is it possible to optimize the 
treatment regimen? 
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More than 80 cross-sectional, case-control and prospective cohort studies have 
been published dealing with the relationship between homocysteine and arterial 
vascular disease [1]. Most but not all studies demonstrated a relationship 
between elevated plasma homocysteine levels and an increased risk for vascular 
disease. In 1976 Wilcken, et al. were the first to report on 25 patients with 
coronary artery disease of whom 7 patients had elevated homocysteine levels 
after loading with methionine in the range of obligate heterozygotes of 
cystathionine β-synthase [2]. In 1985, Boers reported that patients with 
premature peripheral vascular disease and cerebrovascular arterial occlusive 
disease had post load hyperhomocysteinemia in 28% of the cases[3]. These 
findings were confirmed in 1991 by Clarke et al., who showed that post-load 
hyperhomocysteinemia is associated with premature coronary artery disease, 
cerebrovascular disease and peripheral arterial disease[4]. A meta analysis of 27 
reports from 1988 to1994 on 2500 patients with coronary artery disease, 900 
with cerebrovascular disease and 700 with peripheral disease showed a 
calculated summary odds ratio as an estimation of the relative risk in persons 
with elevated homocysteine levels of 1.7 (95% CI 1.5-1.9) for coronary artery 
disease, 2.5 (95% CI 2.0-3.0) for cerebrovascular disease and 6.8(95% CI 2.9-
15.8) for peripheral arterial disease[5].  
The European Concerted Action Project on hyperhomocysteinemia and vascular 
disease was started to provide robust confirmation of hyperhomocysteinemia 
being associated with arterial occlusive disease and to determine possible 
interactions with the established risk factors[6]. Fasting and post-load 
homocysteine levels in the upper quintile of the distribution of levels were 
considered hyperhomocysteinemic. In this population of 750 cases and 800 
controls with relative low cut-off points, the odds ratio for arterial occlusive 
disease was 2.2 (95% CI: 1.7-2.7) of fasting plasma homocysteine levels and 2.1 
(95% CI: 1.7-2.7) of post load hyperhomocysteinemia. These odds ratios did not 
change after adjustment for other risk factors suggesting that mild 
hyperhomocysteinemia is an independent risk factor for arterial vascular disease. 
In contrast to earlier meta analyses, the odds ratios for coronary artery disease, 
Homocysteine in coronary artery disease 
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cerebrovascular disease and peripheral disease were not different. More recent 
meta-analysis demonstrated that stronger associations were observed in 
retrospective studies where homocysteine was measured in blood collected after 
the onset of disease than in prospective studies among individuals who had no 
history of cardiovascular disease when blood was collected [7]. With regard to 
the consistency of the finding of a positive association between 
hyperhomocysteinemia and premature vascular disease, it is important to note 
that to date, more than 20 prospective studies of the topic have been published. 
Among these, the population-based, nested, case-control studies showed that a 5 
µmol/L increment in total plasma homocysteine results in a 20–30% increase in 
cardiovascular risk, which is substantially lower than the 60–90% risk 
enhancement shown in the retrospective case-control studies[7]. The prospective 
studies also suggested that the risk is highest during short-term follow-up and is 
attenuated after 3–4 years. Notably, total plasma homocysteine is a particularly 
strong predictor of cardiovascular events or death in subjects with pre-existing 
illness. 
The meta-analysis of  the Homocysteine Studies Collaboration Group 
demonstrated that after adjustment for known cardiovascular risk factors and 
regression dilution bias in the prospective studies, a 25% lower homocysteine 
level was associated with a 11% (OR, 0.89; 95% CI: 0.83-0.96) lower risk on 
coronary artery disease and a 19% (OR, 0.81; 95% CI: 0.69-0.95) lower risk on 
stroke [8]. So, all meta-analyses confirm that elevated plasma homocysteine is a 
modest independent predictor of coronary artery disease and of stroke risk in 
healthy populations.  
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Homocysteine metabolism 
 
Homocysteine is a sulphydryl-containing amino acid derived from the metabolic 
demethylation of methionine, an essential amino acid. Two pathways, the 
transsulphuration pathway and the remethylation pathway are involved in the 
conversion of homocysteine. 
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Enzymes involved in homocysteine metabolism   
1) CBS: cystathionine β-synthase  
2) MS:  methionine synthase 
3) MTHFR: methylene tetrahydrofolate reductase  
4) BHMT: betaine-homocysteine methyltransferase  
Vitamin B6 and cobalamin are co-factors for cysthathionine β-synthase and methionine 
synthase respectively. Folate and betaine are co-substrates 
MS BHMT 
cobalamin
MTHFR 
CBS B6
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Homocysteine can be irreversibly degraded to cystathionine by cysthathionine β-
synthase (CBS) which requires pyridoxal-5-phosphate, an active form of vitamin 
B6 in order to function adequately[6]. Cystathionine is further converted to 
cysteine by γ-cystathionase. The transsulphuration pathway has a limited 
distribution and is found primarily in organs like kidney and liver. Homocysteine 
can also be metabolized via two methionine-conserving remethylation pathways. 
A substantial portion of homocysteine is remethylated in the liver or the kidney 
using betaine-homocysteine methyltransferase (BHMT) with betaine as methyl 
donor. The second remethylation pathway uses methionine synthase (MS) in the 
conversion of homocysteine to methionine. In this reaction 5-
methyltetrahydrofolate, formed out of 5,10- methylene tetrahydrofolate by 
methylene tetrahydrofolate reductase (MTHFR) serves as methyl donor. MS 
requires the co-factor cobalamin (vitamin B12) for the methyl transport from 5-
methyltetrahydrofolate to homocysteine. MS is activated by S-
adenosylmethionine [7].  The MTHFR dependant methionine synthase 
remethylation pathway is located in almost all tissues. 
 
Association between cystathionine β-synthase deficiency and 
cardiovascular risk  
One of the main regulating enzymes in homocysteine metabolism is 
cystathionine β-synthase (CBS). Mutant CBS enzyme is an important 
determinant of hyperhomocysteinemia and is biochemically characterized, in 
homozygous form, by very high levels of plasma homocysteine, homocystinuria, 
hypermethionemia and hypocysteinemia. This inborn error of metabolism is 
inherited as an autosomal recessive trait and is the most common cause of 
homocystinuria with a worldwide incidence of 1:344.000 living births with the 
highest incidence in Ireland at 1:65.000[1]. The reported world wide incidence 
has been based on new-born screening and may be an underestimation of the true 
incidence. A recent study showed that the incidence of mutated CBS gene in 
homozygous form may be as high as 1:20.500 in a Danish population[2]. Until 
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now, about 100 different mutations have been described in the CBS gene[3], 
which is located on chromosome 21q22.3[4,5]. Relatively common mutations in 
homozygous form in West-European countries responsible for the classical 
homocystinuric phenotype are 833T→C with the amino acid substitution 
isoleucine to threonine(I278T), which confers vitamin B6 responsiveness and in 
Celtic populations the 919G→A with the amino acid change glycine to 
serine(G307S), which represents severe pyridoxine non-responsiveness. 
Together, they represent almost 75% of the homocystinuric alleles analysed[3]. 
Approximately 50% of the patients who are CBS deficient respond to 
pyridoxine, and this responsiveness is constant within sibships[6]. Patients who 
are homozygous for CBS deficiency have a very high risk for arterial and venous 
vascular disease. Pooled data on homozygous CBS deficient patients showed that 
before the age of 30 more than half of the patients had a severe vascular event[6]. 
Recent studies have revealed that providing homocysteine lowering therapy for 
these patients reduces the risk of a major vascular event with about 90 %[7].  
In two early studies, CBS activity was studied in cultured fibroblasts of mild 
hyperhomocysteinemic patients with vascular disease[8,9]. In these patients a 
reduced activity in CBS activity was found resembling heterozygosity for 
classical homocystinuria and it was proposed that such carriership was the cause 
of mild hyperhomocysteinemia. In later studies the association between reduced 
activity of CBS and vascular patients with mild hyperhomocysteinemia could not 
be reproduced [10-12]. Next, molecular genetic studies demonstrated that 
heterozygosity for mutant CBS is at the most a very minor cause for mild 
hyperhomocysteinemia in vascular patients[12-15]. Furthermore, the calculated 
number of individuals heterozygote for CBS deficiency was shown to be too low 
to account for the high incidence of hyperhomocysteinemia in patients with 
premature vascular disease[16]. 
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Association between  methylenetetrahydrofolate reductase deficiency 
and cardiovascular risk  
Patients with severe deficiencies of methylenetetrahydrofolate reductase 
(MTHFR) display a wide range of clinical features such as neurological 
abnormalities, mental retardation and premature vascular disease[2]. Severe 
MTHFR deficiency is the most common inborn error in folate metabolism, still 
very rare with an estimated world wide incidence of 1:3.000.000 living 
births[17]. This inborn error of folate metabolism is inherited as an autosomal 
recessive trait. Severe MTHFR deficiency is biochemically characterized by 
hyperhomocysteinemia and homocystinuria in the presence of hypomethionemia. 
The MTHFR gene has been mapped to 1p36.3 and  in homocystinuric patients 24 
mutations have been identified until now [18-20]. 
In 1988, Kang demonstrated a new MTHFR variant that is very sensitive to 
heating at 46˚C [21] and in 1995, Frosst et al. identified the very common 
thermolabile mutation in the MTHFR gene, 677 C→T converting an alanine to a 
valine codon, which mutation leads to the thermolability of the enzyme [22].  
Subjects who are homozygous for this mutation have residual activities after 
heating that are approximately 30% of those for controls. It is important to note 
that this mutation also decreases specific activity of MTHFR at normal body 
temperature. Prevalence of  this polymorphism in homozygous form is between 
0% and 25% depending upon the population in which prevalence was 
determined [23]. Kang et al. described that MTHFR 677 C→T mutation was 
more common among patients with coronary artery disease compared to controls 
[24]. If elevated homocysteine levels are responsible for the increased risk for 
vascular disease than the thermolabile MTHFR genotype, accompanied by 
higher homocysteine levels, should lead to an increased risk for vascular disease. 
In one of the largest case-control studies on 735 patients with coronary artery 
disease and 1250 controls the calculated odds ratio was 1.21 (95% CI: 0.87-1.68) 
suggesting that the risk for premature vascular disease is not associated with the 
MTHFR TT  genotype[25]. A recent meta analysis of 23 studies indeed revealed 
no significant increased risk of vascular disease among subjects with the TT 
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genotype compared to subjects with the CC genotype [26]. The calculated odd’s 
ratio was 1.12 (95% CI: 0.92-1.37). Nevertheless, patients with TT genotype had 
a plasma homocysteine concentration which was 2.6 µmol/l higher than patients 
with CC genotype. Therefore, the expected odd’s ratio for vascular disease of 
patients with TT genotype compared to CC genotype, based on their 
homocysteine levels, should be about 1.26. This is well within the confidence 
interval of the calculated odds ratio in the above mentioned meta-analysis. It is 
remarkable that the association of this mutation with an increased risk of 
vascular disease differs between continents. Among the European studies, 6 out 
of 11 report an odd’s ratio more than 1 compared to only 2 out of 8 studies in the 
United States and Canada. A possible explanation might be that it is much more 
common to fortify grain products and to take multivitamin supplements in the 
United States and Canada[27]. As shown by several studies, the mutation is 
associated with mild hyperhomocysteinemia mainly in subjects with low-normal 
folate status which makes it likely that the TT genotype emerges as a risk factor 
for vascular disease mainly in populations with a low-normal folate intake[28] .  
Homozygosity for another MTHFR 1298A→C mutation, converting glutamate 
to alanine, in the population is also very common with a prevalence of 10%, 
although, an association between hyperhomocysteinemia and this mutation was 
not found [29,30]. 
 
Association between other enzymes involved in homocysteine 
metabolism and cardiovascular risk 
Until now seven mutations of  methionine synthase (MS) have been described 
[31-33] . There is, however, little evidence that MS polymorphisms play an 
important role in mild hyperhomocysteinemia. Methionine synthase reductase 
(MTRR), a recently identified enzyme, is involved in homocysteine metabolism 
by reductive activation of MS [34]. Recently, a very common missense mutation 
has been identified in the MTR gene. Homozygosity for this mutation, MTRR 66 
A→ G, amino acid substitution isoleucine to methionine, is prevalent in 25-30 % 
and is associated with an increased risk for spina bifida. An association with 
Genetic determinants of hyperhomocysteinemia  
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hyperhomocysteinemia or vascular disease has not been observed [35]. Until 
now 13 mutations of MTRR are identified[34,36].  
So far, 3 mutations have been described in the betaine homocysteine 
methyltransferase (BHMT) gene [37] but mutant BHMT whose remethylation 
reaction is limited to liver and kidney seems not to be associated with 
hyperhomocysteinemia[37].  
 
Treatment of inborn errors of metabolism leading to severe and 
moderate hyperhomocysteinemia 
 
Severe hyperhomocysteinemia 
Homozygous CBS deficiency and homozygosity for severe MTHFR mutations 
will lead to severe hyperhomocysteinemia, with fasting homocysteine levels 
above 50 µmol/l in children and 100 µmol/l in adults and cause, irrespectively of 
the underlying enzymatic defect, a very high risk of premature arteriosclerotic 
and thrombotic events.  
Clinical treatment of patients, homozygous for CBS deficiency, should aim on 
reduction of the major biochemical abnormalities in these patients. For the 50% 
of the patients that are vitamin B6 responsive, vitamin B6 in pharmacological 
doses in combination with folic acid or vitamin B12 or both is the treatment of 
choice. Patients who are non-pyridoxine responsive are advised to use a 
methionine restricted and cysteine supplemented diet mostly in combination with 
some pyridoxine, folic acid and vitamin B12 supplementation. In the treatment 
of the latter patients, the use of betaine is also an option, especially when 
maintaining a dietary restriction is not achievable[38].   
Patients with severe MTHFR deficiency are treated with the high doses of folate 
and riboflavin, a co-factor in MTHFR activity [39] and patients with folate poor 
or non-responsiveness MTHFR deficiency with large doses betaine [40].  
It is therefore obvious that for patients with severe hyperhomocysteinemia 
genetic diagnosis in addition to assessment of enzymatic activity is imperative 
for adequate tailoring of treatment and for genetic counselling. 
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Moderate hyperhomocysteinemia 
Moderate hyperhomocysteinemia can be the result of  genotypes which cause a 
reduced but not total deficient enzyme deficiency with homocysteine levels 
between 40 µmol/l  and 100 µmol/l in adults often combined with a reduced 
folate status [41]. Also combinations of heterozygosity for mutant CBS and 
mutant MTHFR can cause moderate elevated homocysteine levels. Concerning 
patients with moderate hyperhomocysteinemia, it is therefore advisable to 
perform genetic diagnosis and assess enzymatic activity for optimal treatment 
and for genetic counselling. 
 
Mild hyperhomocysteinemia 
There is convincing evidence that mild hyperhomocysteinemia, with fasting 
homocysteine levels above 15 µmol/l, is a risk factor for premature vascular 
disease. It is important to note that mildly elevated homocysteine levels can be 
caused by genetic as well as environmental factors. Several lifestyle 
determinants like folate intake, smoking and coffee intake can modulate 
homocysteine levels causing mildly elevated plasma homocysteine levels. It is 
therefore inaccurate to assume that the increased risk for premature vascular 
disease associated with mild hyperhomocysteinemia can always be attributed to a 
single genetic mutation. A meta-analysis of 12 studies revealed that folic acid 
lowered total plasma homocysteine levels by 25% [42].  Addition of vitamin B12 
led to a further reduction of 7%.  Vitamin B6 did not lower fasting homocysteine 
levels but uncontrolled studies showed that post-load homocysteine levels were 
reduced  21% to 42 %  [43,44]. It might therefore be useful to add vitamin B6 in 
case of elevated post-load homocysteine levels. Until now the treatment of 
mildly elevated homocysteine levels is independent on a possible underlying 
genetic defect.  
Genetic determinants of hyperhomocysteinemia  
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Table 1 
 
Gene  locus  mutation  ref. 
CBS  21q22.3  919 G→A   [3]  
CBS  21q22.3  833 T→C   [3] 
MTHFR  1p36.3  several mutations [18-20] 
MTHFR  1p36.3  677 C→T  [22] 
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Several studies have been published on the relationship between homocysteine 
and vascular disease. However, unlike the overwhelming evidence from 
epidemiological studies, that elevated total plasma homocysteine levels are an 
independent risk factor for cardiovascular disease, the mechanism responsible for 
this increased risk remains unclear.  
 
Homocysteine and the development of atherosclerotic lesions. 
In a post-mortem study of two children with severe hyperhomocysteinemia, Mc 
Cully et al. reported on the existence of severe atherosclerotic disease[1]. The 
lesions involved the large, medium sized and small arteries.  Since then many 
studies have been performed to identify possible adverse effects of homocysteine 
on the vascular wall.  
Several in-vitro studies have been published upon adverse effects of 
homocysteine on functional properties of cultured endothelial cells. Anti-
coagulant properties of cultured endothelial cells, expressed as protein C 
activation, are inhibited when they are exposed to exogenous homocysteine[2,3]. 
The expression of pro-coagulants like tissue factor activity and Factor V activity 
are induced[4,5]. Exogenous homocysteine stimulates the growth and 
proliferation of cultured smooth muscle cells[6,7]. The bioavailability of 
endothelium-derived nitric oxide is impaired by exogenous homocysteine[8]. An 
important concern about many of the above mentioned studies is the fact that the 
required homocysteine concentration used in these studies are more than tenfold 
higher than the plasma concentration of homocysteine in patients. Another 
limitation is that in most studies the free thiol-form of homocysteine is used 
which normally only represents a small fraction of plasma homocysteine in 
patients.  
 
Homocysteine and anatomic changes in coronary arteries 
Several animal studies have been performed, investigating the effect of elevated 
homocysteine levels on the development of atherosclerotic lesions in the arteries. 
With baboons, rats and rabbits, parenteral injection of homocysteine or 
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homocysteine thiolactone led to desquamation of endothelial cells and produced 
structural changes in arteries resembling early atherosclerotic lesions[9,10,11]. In 
a more recent study using minipigs with moderate hyperhomocysteinemia, 
structural changes in large conduit arteries as in resistance vessels could be 
demonstrated[12]. 
Despite the fact that in different animal models a relationship between 
atherosclerotic lesions and homocysteine could be determined, coronary 
angiographic studies show only a weak correlation between the number of 
coronary stenoses or the number of involved coronary vessels and elevated 
plasma homocysteine levels[13,14,15,16].  Important shortcomings of the above 
mentioned studies are that the investigators used visual estimation of lesion 
severity to define whether a vessel was significantly diseased. Visual estimation 
of lesion severity overestimates the percent stenosis compared to estimation of 
lesion severity using quantitative coronary angiography[17]. A study using 
quantitative coronary angiography to evaluate the severity of atherosclerosis in 
coronary arteries in relationship with plasma homocysteine levels is presented in 
chapter 6 of this thesis. 
 
Homocysteine and endothelial function 
Evidence is accumulating that elevated homocysteine causes endothelial 
dysfunction[18].  Mechanisms responsible for endothelial dysfunction in 
hyperhomocysteinemia are poorly understood. Several investigators 
demonstrated that homocysteine reduces the bioavailability of NO and enhances 
smooth muscle cell proliferation, both of which are important markers of athero-
thrombotic disease[18]. Recently, it was hypothesized that 
hyperhomocysteinemia may stimulate the formation of asymmetrical 
dimethylarginine, an endogenous inhibitor of NO synthase[19]. Homocysteine 
may also impair the function of endothelium-derived hyperpolarizing factor, a 
vasodilatator substance released by the vascular endothelium[20]. De Vriese et 
al. demonstrated that folates can restore impaired endothelium-derived 
hyperpolarizing factor instantly[21] .  
   Chapter 4  
 33
Endothelial function related to nitric oxide release can be assessed in humans 
non-invasively, using flow-mediated dilatation of the brachial artery[22].  An 
association between hyperhomocysteinemia and impaired flow mediated 
vasodilatation of the brachial artery was observed for the first time in children 
homozygous for cystathionine β-synthase deficiency who have very high levels 
of plasma homocysteine[23]. Two other studies demonstrated an impaired flow 
mediated vasodilatation of the brachial artery in subjects with mild to moderate 
hyperhomocysteinemia[24,25]. However, not all the studies with humans show a 
relationship between an increased total plasma homocysteine levels and impaired 
endothelial function using a fore arm model[26,27,28]. Some investigators have 
focused on different forms of homocysteine in plasma demonstrating that 
reduced homocysteine is related to endothelial dysfunction but not free oxidized 
homocysteine or protein bound homocysteine[29].  
The clinical relevance of flow-mediated vasodilatation was recently 
demonstrated by Gokce et al. They demonstrated that flow-mediated 
vasodilatation of the brachial artery predicts short-term cardiovascular events 
following vascular surgery[30]. Modena et al. demonstrated that improvement of 
more than 10% of the flow-mediated vasodilatation in the fore-arm was able to 
predict events[31] . It is important to note that the variance of flow-mediated 
vasodilatation in an individual patient is larger than the differences described in 
the above mentioned studies. It is therefore difficult to evaluate a therapeutical 
intervention in an individual patient using the fore-arm model. Factors known to 
impair endothelial function in the coronary circulation are also associated with 
impaired flow mediated dilatation in the brachial artery[32,33].  Acetylcholine is 
widely used as a standard substance to test endothelial function in human 
coronary arteries[34]. In subjects with normal coronary vessels, acetylcholine 
induces vasodilatation of epicardial coronary vessels and an increase of coronary 
blood flow (CBF) of 50% or more[35]. In patients with atherosclerosis, or in the 
presence of risk factors for vascular disease like hypercholesterolaemia, 
hypertension, diabetes mellitus or smoking, acetylcholine induces paradoxical 
vasoconstriction of epicardial conductance vessels, expressed as a decrease in 
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mean segment diameter (MSD) and minimal obstruction diameter (MOD), and a 
smaller increment of CBF[34]. An increase of CBF less than 20% after the 
administration of acetylcholine in coronary vessels is associated with increased 
cardiovascular mortality[36,37]. Endothelial cells synthesize and release 
vasoactive mediators and thereby modulate vascular tone. Nitric oxide (NO) and 
prostacyclin are the best characterized vasodilatators and are largely responsible 
for endothelium dependant vasodilatation in epicardial coronary vessels. 
However, not all endothelium-dependant relaxation can be explained by nitric 
oxide  and prostacyclin. Compelling evidence is provided for the existence of 
another factor, endothelium-derived hyperpolarizing factor that is especially 
important in resistance vessels[38]. In humans with coronary atherosclerosis, 
endothelial vasodilatator function is not confined only to epicardial conductance 
vessels but extents also to the coronary resistance vessels. CBF in the absence of 
obstructive lesions is regulated mainly by the coronary resistance vessels[39]. 
Abnormal CBF changes during administration of endothelium dependant 
vasodilatators like acetylcholine in patients without obstructive coronary artery 
disease are associated with cardiovascular morbidity and mortality[35,40]. Since 
homocysteine is associated with cardiovascular mortality and morbidity[14,41], 
these changes in CBF may therefore explain, at least partially, the role of 
homocysteine in cardiovascular disease. 
Recently the effects of homocysteine-lowering treatment on endothelial function 
using flow-mediated vasodilatation of the brachial artery was studied. Although 
some investigators could demonstrate a beneficial effect of folic acid on flow-
mediated vasodilatation[42,43] the results are not unequivocal [44,45]. In this 
thesis we describe the effect of homocysteine-lowering treatment on coronary 
endothelial function 
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Introduction  
More than 80 cross-sectional, case-control and prospective cohort 
studies have been published upon the relationship between 
homocysteine and arterial vascular disease [1]. Despite overwhelming 
epidemiological evidence confirming that hyperhomocysteinemia is an 
independent risk factor for vascular disease, the exact causal 
relationship remains to be proven. Methylenetetrahydrofolate reductase 
(MTHFR) is a regulating enzyme in folate-dependant homocysteine 
remethylation because it catalyses the reduction of 5,10 
methylenetetrahydrofolate to 6[S] 5-methyltetrahydrofolate (5-MTHF), 
the natural circulating form of folate in plasma. 6[S]5-MTHF serves as 
methyl donor for the conversion of homocysteine to methionine. In 
1995 Frosst et al. identified a common mutation in the MTHFR gene, a 
transition at nucleotide 677(C→T) converting an alanine to a valine [2].  
Patients who are homozygous for this variant have an elevated total 
plasma homocysteine [3]. Recently it was demonstrated convincingly 
that these subjects, 10 to 20% of the population, have an increased 
cardiovascular risk [4]. Many studies have demonstrated  that elevated 
homocysteine can be lowered by the intake of folic acid in doses 
ranging from 400 µg to 10 mg/day [5].  Recently, we demonstrated a 
beneficial effect of homocysteine-lowering therapy using long-term 
folate therapy, 5 mg, on coronary endothelial function in 
hyperhomocysteinemic patients, a surrogate endpoint for cardiovascular 
events [6]. In addition, Doshi et al.  demonstrated that 5-
methyltetrahydrofolate (5-MTHF)  had a direct beneficial effect on 
endothelial function, independent of plasma homocysteine levels [7].  
These results suggest that high concentrations of the natural isomer of 
5-MTHF in plasma may be beneficial in cardiovascular disease. 
Whether these effects are related to a reduced activity of  the MTHFR 
enzyme or due to a better bioavailability of 5-MTHF is unclear. Orally 
administered folic acid needs to be reduced and converted to 
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tetrahydrofolate before it can become metabolic active. In subjects 
homozygous for the MTHFR 677 C→T mutation, it may be speculated 
that the direct administration of 5-methyltetrahydrofolate instead of 
folic acid can facilitate the remethylation of homocysteine into 
methionine. Otherwise, it is possible that the efficacy of 5-MTHF is 
better independently of a reduced activity of  the MTHFR enzyme. 5-
MTHF is available as a mixture of  6[S] and 6[R] racemates. Although, 
it is assumed that only 6[S] 5-MTHF is bio-active, the possible 
biological effects of 6[R] 5-MTHF are not clear. The aim of this study 
was to determine the pharmacokinetic properties of a single dose of 
orally administered 6[R,S] 5-MTHF, a commercially available racemic 
mixture of the two diastereoisomers of 5-MTHF, versus folic acid in 
cardiovascular patients with homozygosity for the MTHFR 
polymorphism (TT genotype) compared to patients with the wild type 
genotype (CC). 
 
Methods 
Patient selection: 
This study is a open controlled, 2 way, 2 period randomised cross over 
study with a one week run in and a one week wash out period. Patients 
with established coronary heart disease were screened by DNA analysis 
for the presence of the MTHFR 677C→T polymorphism . Genomic 
DNA was extracted from peripheral blood lymphocytes by a standard 
procedure, and mutation analysis was performed essentially as described 
by Frosst et al.[2]. All patients have given informed consent. Twelve 
patients with the TT genotype MTHFR and twelve patients with wild 
type MTHFR enrolled in the study. 
The groups were matched for age, sex and body weight. Inclusion of 
patients required a body weight within 20% of normal values according 
to the Metropolitan Height and Weight Tables. No clinically important 
abnormal physical findings were tolerated. In all subjects enrolled in the 
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study at baseline and after four weeks, blood samples were analysed for 
liver and renal function, haematology, urinalysis and vitamins. Patients 
with a myocardial infarction in the past 3-month were excluded, as well 
as patients with relevant history of liver disease, renal disease and 
gastrointestinal disease. Medication involved in homocysteine 
metabolism, the use of vitamins or blood donation in the past three 
months were not allowed. Users of significant amounts of tobacco 
(10/day), alcohol (> 40 gr/day) or drugs were excluded. 
Patients did not take food or drinks, apart from water, 12 hours before 
administration of the folic acid or 5- MTHF and up to 4 hours after the 
administration of the medication. In the period of the study patients 
followed a stable diet which guaranteed a stable intake of 200 µg folate 
a day (the recommended daily allowance). The study medication 
consisted of a single oral dose of folic acid (folinaR), 5 mg or 6 [R,S] 5-
MTHF (PrefolicR), 5 mg. 
 
Study schedule 
Each patient underwent a pre-study assessment within 2 weeks before 
run in period. During the first study period the patients received a single 
oral dose of either 5 mg folic acid or 5 mg 6 [R,S] 5-MTHF, dissolved 
in 50 ml distilled water according to the randomisation list. Patients 
were blinded for treatment. A wash out period of one week followed 
after which the patients crossed over to the other treatment schedule. 
Administration of the folic acid or 5-MTHF to the fasting patients was 
performed between 07.00 and 09.00 a.m. 
 
Blood samples: 
Venous blood samples were taken at the following times: 0 (pre-dose), 
0.5, 1, 2, 3, 4, 5, 6, 8, 10 and 12 hours following the administration of 
either folic acid or 6[R,S] 5-MTHF. The blood samples were collected 
in heparinized tubes and put on ice immediately and within 30 minutes 
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centrifuged at 3000 x g for 15 minutes at 4ºC. The supernatant plasma 
was transferred to a polypropylene tube containing sodium ascorbate 
and stored at –200 C.  
 
Analytics: 
The plasma concentrations of the [6R] and [6S] 5 MTHF 
diastereoisomers were determined by a validated stereoselective 
method. After an ion-exchange step of purification from the biological 
matrix, 5-MTHF diastereoisomers are resolved by a stereospecific 
enzymatic reaction, using 5-MTHFR. At the end of the reaction, 
aliquots of the samples were analysed by reverse phase high 
performance liquid chromatography (HPLC) with fluorescence 
detection. With this method the concentrations in plasma of the 
diastereoisomers in the low baseline range (3-4 ng.ml-1) are determined 
with an inter-assay coefficient of variation of 10%. The limit of 
quantification for 6[R] 5-MTHF is kept at 5 ng.ml-1 [8]. The following 
parameters were calculated from the plasma concentrations of [6R] and 
[6S] 5-MTHF acid stereoisomers obtained up to 12 hours after 
administration of single dose folic acid or 5-MTHF: Cmax (ng.ml-1)(the 
highest concentration of the diastereoisomer in plasma), t max 
(hours)(the time when Cmax. is achieved), C0-12z (ng.ml-1)(the 
concentration of the diastereoisomer at sampling time z), AUC 0-12z 
(The area under the curve of the plasma concentration versus time up to 
sampling time z), AUC∞ (the area under the curve of the plasma 
concentration versus time using the equation: AUC∞=AUCz+Cz.λz-1) 
and   t1/2 (hours)  Plasma homocysteine levels were determined at 
baseline, 2 hours, 4 hours and twelve hours after taking the vitamins, 
using high performance liquid chromatography as described by te Poele 
et al [9]. 
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Statistics: 
Baseline characteristics are summarised by appropriate descriptive 
statistics. Pharmacokinetic parameters are analysed using variance 
analysis considering the following factors in the model: treatment 
period, category and sequence. The treatment effect and the treatment 
category interaction are tested at a 0.05 level. A log transformation is 
carried out on AUCz, AUC∞ and Cmax before performing ANOVA. 
For presentation the point estimates (mean, SD and 95% confidence 
intervals) are converted back in the original scale. 
 
Results 
In 157 patients screened for the TT MTHFR mutation, we found 14 patients who 
were homozygous for this mutation. Of 27 patients initially included  24 patients 
completed the study. Three patients were excluded from the study due to a 
protocol violation, two patients with a TT genotype and one patient with the CC 
genotype. Baseline characteristics of the participating patients are listed in Table 
1.  
 
Table 1 
Baseline characteristics   
  
 N=10(TT) N=14(CC)  p value† 
 
Age (years) 56.9 ( range 46-64) 57.2 (range 46-66) 0.91 
Sex (male/female) 8/2 11/3  0.55 
Homocysteine (µmol/l) 26.8 (18.1)* 15.4 (3.5) <0.05  
Folate 13,5 (5.7) 19.1 (17.8) 0.35 
Vitamin B12 225 (112) 230 (88) 0.89 
Vitamin B 6 49 (17) 44 (12)  0.47 
Total cholesterol (mmol/l) 5.69 (1.41) 5.16 (0.76) 0.25 
Triglycerides (mmol/l) 2.05 (1.1) 2.11 (1.0) 0.89 
Glucose (mmol/l) 5.7 (1.8) 7.2 (2.4) 0.11 
Kreatinine (µmol/l) 101 (11.6) 101 (39.0) 0.99 
*SD between brackets, † Student T test for equality of means or Chi square test where appropriate 
 
Pharmacokinetic study with 5-MTHF and folic acid 
 46
Mean fasting total plasma homocysteine levels (tHcy) in the patients TT 
genotype was 26.8 µmol/l (SD 18.2) compared to 15.4 µmol/l (SD 3.5) in the 
patients with CC genotype (p<0.05). Total plasma folate was 13.5 nmol/l (SD 
5.7) in the group with TT polymorphism compared to 19.1 nmol/l (SD 17.8) in 
the group with CC polymorphism (p=0.35). No other significant differences 
were found between the two groups.  
One week after the completion of the study plasma folate levels were increased 
from 13.5 to 24.5 nmol/l in the group with TT polymorphism compared to no 
change in the group with the CC polymorphism (p<0.05). Vitamin B12 and 
vitamin B6 did not change during follow-up.  The administration of the single 
dosage of 5 mg folic acid or 5 mg 5-MTHF did not influence plasma 
homocysteine levels during the follow-up of 12 hours, irrespective of the patients 
genotype. In both groups, homocysteine levels did not change at follow-up after 
one week.  
 
Figure 1: Plasma level 6[S] 5-MTHF (ng.ml-1) 
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Genotype and treatment 
6[S] 5-MTHF plasma concentration (ng.ml-1) in patients with MTHFR CC genotype (▲) 
or TT genotype (●) following the administration of 6[R,S] 5-MTHF. 
6[S] 5-MTHF plasma concentration (ng.ml-1) in patients with MTHFR CC genotype (■) 
or TT genotype (♦) following the administration of folic acid. 
Time (hrs) after single dosis 
5-MTHF administration 
▲= CC genotype  
●= TT genotype 
 
Folic acid administration 
■= CC genotype 
♦= TT genotype 
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Pharmacokinetic properties of  6[R,S] 5-MTHF versus folic acid 
The main pharmacokinetic parameters following both treatment strategies for the 
6[S] 5-MTHF and 6[R] 5-MTHF diastereoisomers are listed in Table 2.  All 
pharmacokinetic parameters demonstrate that the bioavailability of 6[R,S]5-
MTHF acid is higher compared to folic acid.  The peak concentration of the 
natural diastereoisomer 6[S] 5-MTHF following the administration of  5-MTHF 
is more then seven times higher compared to the peak concentration of 6[S] 5-
MTHF following the administration of folic acid , 129 ng/ml (SD 42.4) versus 
14.1 ng/ml (SD 9.4)(p<0.001) respectively. The peak concentration of the 
diastereoisomer 6[R] 5-MTHF following the administration of 5-MTHF 
compared to folic acid is 144 ng/ml (SD 75) versus 42 ng/ml (SD 40)(p<0.001) 
respectively.  
 
Table 2  
 
Pharmacokinetic parameters for 6[S] 5-MTHF after administration of either folic 
acid or 5-MTHF  
 
  Folic acid  5-MTHF  
  n=24  n=24 p value† 
 
Ke  0.17 (0.1)*  0.42 (0.18) p<0.001 
T1/2  4.9 (2.5)  2.7 (2.6) p<0.01 
Tmax  2.3 (0.8)  1.25 (0.53) p<0.0005 
Cmax  14.1 (8.9)  129 (33) p<0.0001 
AUC 0-12  73 (39)  383 (113) p<0.0001 
AUC 0-∞  96 (48)  405 (117) p<0.0001 
 
*SD between brackets, † Student T- test for equality of means 
 
Influence of MTHFR 677C→T genotype on the pharmacokinetic properties 
of 6[R,S] 5-MTHF 
The main pharmacokinetic parameters of the biological active 6[S] 5-MTHF 
diastereoisomer for both treatment strategies in relationship with the patients’ 
genotype are listed in Table 3. No significant differences in pharmacokinetic 
parameters exist between patients with the TT genotype and patients with CC 
genotype. Figure 1 shows the 12 hours curve follow-up of 6[S] 5-MTHF in 
ng/ml after oral administration of folic acid and 5-MTHF in both genotype 
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groups. Data on the 12 hours curve follow-up of 6[R] 5-MTHF are essentially 
the same (data not shown)  
 
Table 3 
 
Pharmacokinetic parameters for 6[S] 5-MTHF after administration of 
either folic acid or 5-MTHF in patients with (TT)  and (CC ) genotype 
 
 Folic acid   5-MTHF 
genotype TT   CC  p value† TT   CC  p value 
Ke  0.15(0.1)*0.17(0.1) 0.56  0.32(0.1) 0.35 (0.2) 0.66  
T ½  5.0(2.0) 4.8(2.9) 0.83  2.36(0.7) 2.82(3.5) 0.69 
T max 2.4(0.8) 2.3(0.8) 0.66  1.3(0.5) 1.2(0.5) 0.88 
C max  14(11) 14(7)  0.83  101 (29) 107(36) 0.66 
AUC 0-12 72(39) 74(41) 0.90  303 (105) 329 (121) 0.58   
AUC 0-∞ 99(37) 94(55)  0.82  312 (111) 340 (123) 0.35 
 
* SD between brackets, † ANOVA one way analysis 
 
Figure 2: plasma level of 6[R] 5-MTHF (ng/ml-1) 
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Sequence of treatment: 
6[R] 5-MTHF plasma concentration (ng.ml-1) in patients after folic acid intake in the first 
period (♦), 6[R] 5-MTHF plasma concentration (ng.ml-1) in patients after folic acid intake 
in the second period (■) 
6[R] 5-MTHF plasma concentration (ng.ml-1) in patients after 6[R,S] 5-MTHF intake in 
the first period(▲) and patients after 6[R,S] 5-MTHF intake in the second period(●). 
 
5-MTHF administration 
▲= 5-MTHF (followed by folic acid ) 
●= 5-MTHF (preceded by folic acid) 
 
Folic acid administration 
♦= folic acid (followed by 5-MTHF) 
■= folic acid (preceded by 5-MTHF) 
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Pharmacokinetic properties of 6[R,S] 5-MTHF in relationship with the 
treatment sequence 
The sequence of treatment with folic acid or 5-MTHF (either folic acid or 6[R,S] 
5-MTHF as the first drug) did not influence the results of the pharmacokinetic  
parameters for the 6[S] 5-MTHF diastereoisomer (data not shown). The 
washout curve for the 6[R] 5-MTHF diastereoisomer showed that in the 
case that folic acid was given in the first period the metabolic inactive 
6[R] 5-MTHF diastereoisomer was not present in the plasma (detection 
limit < 5 ng/ml). However, if folic acid was given in the second period, 
levels of 6[R] 5-MTHF became clearly detectable in plasma. This was 
irrespective of the patients genotype (Figure 2). 
 
Discussion 
This study demonstrated a higher bioavailabity of orally administrated 
racemic 6[R,S] 5-MTHF, 5 mg compared to folic acid, 5mg. The effects 
were not influenced by the MTHFR 677TT genotype of the patient. 
Plasma homocysteine levels did not alter following the administration 
of a single dosage of either folic acid or 6[R,S] 5-MTHF acid. 
Pharmacokinetic properties of folic acid and 6[R,S] 5-MTHF 
In our study a prompt rise of 6[S] 5-MTHF, the natural isomer 
possessing biological activity [10] , within 1 to 3 hours following the 
administration of folic acid or 6[R,S] 5-MTHF was shown with peak 
concentrations who were sevenfold or more higher than baseline 
concentrations. Our data, with respect to the pharmacokinetic profile, 
are consistent with a previous study evaluating the effect of oral 
administration of folic acid in patients with the TT polymorphism 
compared to patients with the CC polymorphism where comparable 
rises of the 6[S] 5-MTHF diastereoisomer have been seen[11]. It is to be 
expected that 5-MTHF levels are proportionally lower following the 
administration of folic acid compared to 6[R,S] 5-MTHF because 
6[R,S] 5-MTHF is directly available following absorption in the 
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intestinal cell while folic acid needs to be metabolised first into 
tetrahydrofolate. Depending upon folate supply tetrahydrofolate can be 
transported into the portal circulation, converted to 6[S] 5-MTHF or be 
stored in tissue as a tetrahydrofolate. This prolonged biochemical 
pathway can be a possible explanation for the difference in the 
pharmacokinetic parameters. Some studies used 5-MTHF as 
pharmacological agent to improve endothelial function is vascular 
patients [7]. It can be speculated that these high levels of circulating 
metabolic active folates may be responsible for the observed direct 
improvement of endothelial function . 
Folates in relation to genotype: 
Our data demonstrates that there are no differences with respect to the 
pharmacokinetic properties of both folic acid and 6[R,S]5-MTHF in 
relation to the patients’ genotype. Mutations in MTHFR have been 
associated with a lower proportion of 5-MTHF and a higher proportion 
of formylated folates [12]. This, because of a decreased MTHFR 
activity resulting in a lower rate of reduction of 5,10-methyleneTHF to 
5-MTHF, leading to increased availability of 5,10-methylene-THF for 
oxidation to the formylated folate forms. Our results suggest that the 
activity of MTHFR in vivo is not the rate-limiting step in the conversion 
of folic acid to 5-MTHF.  
The sequence of therapy: 
The sequence of administration of either folic acid or 6[R,S]5-MTHF 
did not influence pharmacokinetic parameters with respect to the plasma 
level of  the physiologically active form 6[S] 5-MTHF. Since oral 
applied 5-MTHF consists of a racemic mixture of  6[S]5-MTHF and 
6[R] 5-MTHF it can be explained that the 6[R] 5-MTHF isomer can be 
detected in the plasma. Compared to plasma levels of 6[S] 5-MTHF, 
plasma levels of 6[R] 5-MTHF reach higher peak concentrations and  
still have a higher plasma concentration 12 hours after the intake. These 
findings suggest that this isomer has a slower clearance from the 
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plasma, possibly due to the non-natural form of 5-MTHF. Our findings 
are consistent with a previous study investigating the effects of high 
dosage 6[R,S] 5-MTHF demonstrating a higher plasma concentration 
and slower plasma clearance of 6[R] 5-MTHF compared to 6[S] 5-
MTHF [13]. In that study it was demonstrated that protein binding of 
6[R] 5-MTHF is 88% compared to 56% of the 6[S] 5-MTHF with a 
decreased renal clearance as a consequence.  
If folic acid was given as the first drug, 6[R] 5-MTHF could not be 
detected in the plasma. This is to be expected since folic acid will only 
be metabolised into its natural active isomer. However, when folic acid 
was given in the second period (one week after the administration of the 
racemic 6[R,S] 5-MTHF), 6[R] 5-MTHF could be detected in the 
plasma, even at relative high levels (figure 2). A previous study revealed 
that the clearance rate of 6[R] 5-MTHF is about 4 times slower than for 
the 6[S] 5-MTHF [14]. However, this can not explain the fact that one 
week after a single bolus 6[R,S] 5-MTHF we found relative high levels 
of 6[R] 5-MTHF only after we supplied folic acid. The 6[R] 5-MTHF 
isomer was not detectable at baseline, thus before the administration of 
folic acid.  It seems therefore less likely that the difference in plasma 
protein-binding between 6[S] 5-MTHF and 6[R] 5-MTHF explains this 
phenomenon since the 6[R] 5-MTHF isomer was not detectable in 
plasma at baseline. Our results suggest that the 6[R]5-MTHF isomer is 
stored in the body until it is released following the administration of a 
relative large dosage of folic acid. Folates are stored in tissues, mainly 
in the liver where folates are bound tight by cytosolic and mitochondrial 
folate binding proteins. This binding may not be stereospecific. The 
biological effects of  6[R] 5-MTHF binding are unclear. Mader et al. 
reported that no serious short-term side-effects were seen in patients 
receiving high doses of 6[R,S]5-MTHF[13]. Since 6[R] 5-MTHF is not 
metabolised, it can be speculated that it may inhibit regulatory enzymes 
related to folate and homocysteine metabolism.  Secondly , the 
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bioavailabity of 6[S] 5-MTHF may be reduced due to competition with 
the 6[R] 5-MTHF diastereoisomer.  
Genotype of the patient and homocysteine levels 
Several investigators have demonstrated that subjects who are 
homozygous for the TT polymorphism have an elevated tHcY only 
when plasma folate is low [3, 15, 16, 17]. Plasma folate levels  in the 
group of patients with TT polymorphism were relatively low compared 
to folate levels in the CC group. Obviously, the administration of a 
single dosage of folic acid or 6[R,S] 5-MTHF did not alter 
homocysteine levels during the study suggesting that long-term 
treatment is mandatory. 
Conclusion: 
Our results demonstrates that 6[R,S] 5-MTHF has a different pharmacokinetic 
profile compared to folic acid, irrespective of the patients’  MTHFR 677 C→T 
genotype. Although the clinical significance of these differences require further 
investigation, the prompt sevenfold rise in the concentration of the natural isomer 
may be a promising  feature of 5-MTHF in the treatment of vascular disease. The 
clinical consequences of relative high plasma levels of the non-natural isomer, 
6[R] 5-MTHF, following the administration of 6[R,S] 5-MTHF are unknown. 
Since our study suggests that this isomer is stored in the body, further 
investigations of the clinical long-term effects of the racemic 6[R,S] 5-MTHF 
acid are necessary to evaluate possible detrimental effects. 
 
References 
 
1) Refsum H, Ueland PM, Nygård O, et al. Homocysteine and 
cardiovascular disease. Annu Rev Med. 1998;49:31-62 
2) Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, 
Boers GHJ, Den Heijer M, Kluijtmans LAJ, Van Den Heuvel LPWJ, 
Rozen R. A candidate genetic risk factor for vascular disease: a 
common mutation in methylenetetrahydrofolate reductase. Nature 
Genet 1995; 10:111-113 
3) Kluijtmans LAJ, Kastelein JP, Lindemans J, Boers GHJ, Heil SG, 
Bruschke AVG, Jukema JW, van den Heuvel LPWJ, Trijbels FJM, 
   Chapter 5 
 53
Boerma GJM, Verheugt FWA, Willems FF, Blom HJ. Thermolabile 
methylene teterahydrofolate reductase in coronary artery disease. 
Circulation 1997;96:2573-2577 
4) Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 
677C→T polymorphism and risk of coronary heart disease: a meta-
analysis. JAMA. 2002; 288:2023-31 
5) Clarke R, Armitage J. Vitamin supplements and cardiovascular risk : 
Review of the randomized trials of homocysteine lowering vitamin 
supplements. Sem Thromb Hemost 2000;26:341-348 
6) Willems FF, Aengevaeren WRM, Boers GHJ, Blom HJ, Verheugt FWA. 
Coronary Endothelial Function in Hyperhomocysteinemia: 
Improvement After Treatment With Folic Acid and Cobalamin in 
Patients with Coronary Artery Disease. J Am Coll Cardiol. 
2002;40:766-772 
7) Doshi SN, McDowell IF, Moat SJ, Payne N, Durrant HJ, Lewis MJ, 
Goodfellow J. Folic acid improves endothelial function in coronary 
artery disease via mechanisms largely independant of homocysteine 
lowering. Circulation 2002; 105:22-26 
8) Leeming RJ, Pollock A, Melville LJ, Hamon CG. Measurement of 5-
methyltetrahydrofolic acid in man by high-performance liquid 
chromatography. Metabolism 1990;39:902-904 
9) te Poele-Pothoff MT, van den Berg M, Franken DG, Boers GH, Jakobs 
C, de Kroon IF, Eskes TK, Trijbels JM, Blom HJ Three different 
methods for the determination of total homocysteine in plasma. Ann 
Clin Biochem 1995; 32: 218-20 
10) Keresztesy JC, Silverman M. Crystalinne citrovorum factor from liver. J 
Am Chem Soc 1951;73:5510 
11) Stern LL, Bagley PJ, Rosenberg IH, Selhub J. Conversion of 5-
formyltetrahydrofolic acid to 5-methyltetrahydrofolic acid is 
unimpaired in folate adequate persons homozygous for the C677T 
mutation in the methylenetetrahydrofolate reductase gene. J Nutr 
2000;130:2238-42 
12) Rosenblatt, D. S., Cooper, B. A., Lue-Shing, S., Wong, P. W. K., Berlow, 
S., Narisawa, K,Baumgartner, R. J. Folate distribution in cultured 
human cells. Studies on 5,10-CH2-H4PteGlu reductase deficiency. Clin. 
Invest. 1979; 63:1019-1025 
13) Mader RM, Steger GG, Rizovski B, Djavanmard MP, Scheithauer W, 
Jakesz R, Rainer H. Stereospecific pharmacokinetics of rac-5-
methyltetrahydrofolic acid in patients with advanced colorectal cancer. 
Br J Clin Pharmacol  1995; 40:209-15 
14) Mader RM, Steger GG, Rizovski B, Jakesz R, Rainer H. Different 
stereospecific protein binding of tetrahydrofolates to human serum 
albumin. J Pharm Sci. 1994; 83:1247-9. 
15) Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, 
Rosenblatt DS, Genest J, Rozen R. Correlation of a common mutation in 
the methylenetetrahydrofolate reductase gene with plasma 
Pharmacokinetic study with 5-MTHF and folic acid 
 54
homocysteine in patients with premature coronary artery disease. 
Arterioscler. Thromb.Vasc Biol 1997;17:569-573 
16) Harmon ,DL, Woodside JV, Yarnell JWG, McMaster D, Young IS, 
McCrum EE, Gey KF, Whitehead AS, Evans AE. The common 
“thermolabile “ variant of methylenetetrahydrofolate reductase is a 
major determinant of mild hyperhomocysteinemia. QJMed 
1996;89:571-77 
17) Kang SS, Wong PWK, Norusis M. Homocysteinemia due to folate 
deficiency. Metabolism 1987;36:458-6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Chapter 5 
 55
  56
6 
Chapter 
 
 
 
 
 
 
 
Thermolabile methylenetetrahydrofolate 
reductase in coronary artery disease  
 
 
 
 
 
 
 
 
 
 
 
Leo A. J. Kluijtmans, John J. P. Kastelein, Jan Lindemans, Godfried H. J. Boers, Sandra 
G. Heil, Albert V. G. Bruschke, J. Wouter Jukema, Lambert P. W. J. van den Heuvel, 
Frans J. M. Trijbels, Geert J. M. Boerma, Freek W. A. Verheugt, Frank Willems, Henk J. 
Blom,  
Circulation. 1997;96 : 2573-7
   Chapter 6 
 57
Introduction 
 
A recent meta-analysis by Boushey et al. of 27 independent studies in which 
plasma homocysteine concentrations were quantitatively related to 
atherosclerotic disease demonstrated that mild hyperhomocysteinemia is an 
independent and graded risk factor for cerebral, peripheral, and coronary artery 
disease [1]. Elevated homocysteine concentrations may originate from nutritional 
deficiencies in cofactors or co-substrates of enzymes involved in homocysteine 
metabolism or from molecular defects in genes coding for enzymes crucial in 
this metabolism.[2,3,4,5]. 
The enzymes pivotal in homocysteine metabolism are cysthationine β synthase 
(CBS), the first enzyme in homocysteine transsulfuration, and methylene 
tetrahydrofolate reductase (MTHFR), which is involved in the folic acid 
dependent remethylation of homocysteine to methionine. Both genes have been 
cloned and characterized,[6,7] and several mutations have been reported 
[8,9,10,11,12] in patients with a homozygous deficient phenotype. Heterozygotes 
for either CBS or MTHFR deficiency often have elevated homocysteine 
concentrations. However, the frequency of heterozygosity for CBS and MTHFR 
deficiency is too low to account for the frequency of mildly elevated 
homocysteine levels in patients with cardiovascular disease.[13] MTHFR is a 
flavoprotein that reduces 5,10-methylenetetrahydrofolate to 5-
methyltetrahydrofolate, the predominant circulating form of folate. In 1988, 
Kang et al [5] described a new MTHFR variant with thermolabile properties. 
Individuals with this MTHFR variant have decreased specific MTHFR activity in 
lymphocytes (<50% of the control mean), have increased thermolability after 
preincubation at 46°C, and may have elevated plasma homocysteine 
concentrations. In other studies, the same group reported an increased incidence 
of this MTHFR variant in patients with coronary artery disease [14] compared 
with control subjects (17% versus 5%, respectively), and they were able to 
correlate the incidence of thermolabile MTHFR to the severity of coronary artery 
disease.[15] In a Dutch study, this thermolabile MTHFR was found to be the 
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cause of abnormal homocysteine metabolism in 11 of 39 hyperhomocysteinemic 
vascular patients (28%)[16]. Recently, Frosst and coworkers17 were able to 
identify a relatively common 677C→T mutation in the MTHFR gene, which 
substituted a conserved alanine by a valine residue. Individuals who are 
homozygous for this mutation often have elevated homocysteine 
concentrations,[17 18] especially in combination with a low folate status.[19 20] 
In the present study, we investigated the prevalence of the 677C→T mutation in 
a well-defined population of 735 male cad patients and in 1250 population-based 
control subjects and assessed the association of this mutation to serum 
homocysteine concentration. Several studies have investigated the homozygous 
677C→T mutation as a risk factor for cad but with conflicting results,[21, 22, 23, 
24, 25, 26] probably because of the relatively small numbers of individuals 
included in each study separately. We therefore performed a meta-analysis of 
eight case-control studies reporting data on the MTHFR genotype distribution to 
estimate the relative risk of the homozygous (+/+) genotype for coronary artery 
disease. 
 
Methods 
 
Study Population 
We studied 735 male patients with angiographically assessed coronary artery 
disease enrolled in the REGRESS, which was conducted under auspices of the 
Interuniversitary Cardiology Institute The Netherlands. REGRESS is a double-
blind, placebo-controlled, multicenter trial designed to assess the effects of lipid-
lowering therapy with pravastatin on progression and regression of coronary 
artery disease in 885 male patients with normal to moderately elevated serum 
cholesterol levels (4 to 8 mmol/L). The overall study design and inclusion 
criteria of patients have been described extensively[27]. A large control group 
was constructed, consisting of individuals recruited from several published [28, 
29] and unpublished Dutch case-control studies (L.A.J.K., H.J.B., Van der Put, 
Den Heijer, and Rosendaal, unpublished results), which resulted in a control 
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group consisting of 1250 unrelated population-based control subjects. All 
677C→T mutation analyses were performed in our laboratory. 
For a summary quantitative risk assessment of the 677CT mutation in coronary 
artery disease, we evaluated eight international case-control studies,[21, 22, 23, 
24, 25, 26, 29] including the present one. In this analysis, we confined ourselves 
to case-control studies in which MTHFR genotype distributions among both 
coronary artery disease patients and control subjects either 
were given or could be calculated from their data. We calculated the MTHFR 
genotype distribution and odds ratios of the (+/+) genotype for coronary artery 
disease in each study separately and for all studies combined.  
 
MTHFR Genotype Analysis 
Genomic DNA was extracted from peripheral blood lymphocytes by standard 
procedure, and mutation analysis was performed essentially as described by 
Frosst et al.[17] Electrophoresis in a 4% agarose gel followed by ethidium 
bromide staining and UV illumination allowed detection of mutated alleles.  
 
Homocysteine Determination 
After an overnight fast, blood was drawn from the coronary artery disease 
patients for an assessment of fasting homocysteine concentrations, and serum 
was stored at -70°C until analysis. Homocysteine concentrations were 
determined by high-performance liquid chromatography with use of a 150x4.6-
mm Hypersil ODS column in a high-performance 
liquid chromatography analyzer (Thermo Separation Products) after the thiol 
groups were bound to a fluorescent label (SBD-F).30  
 
Statistical Analysis 
Odds ratios and 95% confidential intervals(CI) were calculated as an estimate of 
the relative risk of the different genotypes in coronary artery disease.[31] 
Differences in genotype distributions were calculated by 2 analysis. To assess the 
relationship between the 677C→T transition and homocysteine concentrations, 
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we calculated median homocysteine concentrations in different genotype groups. 
Differences between homocysteine concentrations in these genotype groups were 
assessed by one-way ANOVA, followed by pairwise t tests on log-transformed 
data. All probability values are two-tailed, and a value of P<.05 was considered 
statistically significant. 
 
Results 
 
MTHFR Genotype Analysis 
The overall frequency for the (+) allele was 31.8% among patients and 29.5% 
among control subjects. The numbers of individuals homozygous for the 677CT 
transition were 70 of 735 coronary artery disease patients (9.5%) versus 106 of 
1250 controls (8.5%; Table 1). The genotype distributions in both groups of 
individuals are consistent with those calculated from the Hardy-Weinberg 
equilibrium. The odds ratios as an estimate of the relative risk of the (+/+) and 
(+/-) genotypes relative to the risk of the (-/-) genotype for coronary artery 
disease were 1.21 and 1.14, respectively (Table 1). We also assessed the relative 
risk of the (+/+) genotype in relation to the risk of individuals with both other 
genotypes. In this model, the risk of the homozygous (+/+) genotype in coronary 
artery disease was 1.14 (95% CI, 0.83 to 1.56).  
 
Table 1.  
Distribution of 677C→T MTHFR variant among patients with coronary 
artery disease and control subjects 
 
  Coronary artery disease patients Control Subjects Odds Ratio (95% CI) 
   (n=735), n (%) (n=1250), n (%) 
  
 +/+    70 (9.5) 106 (8.5)                    1.21 (0.87-1.68) 
   +/-     328 (44.6) 527 (42.2)                 1.14 (0.94-1.38) 
  -/-     337 (45.9) 617 (49.4)                 1.01 * 
 
 *Reference category: odds ratio=1.0. 
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Association Genotype and Total Homocysteine 
Homocysteine concentrations were measured in 515 of 735 coronary artery 
disease patients. The numbers of individuals in the three different MTHFR 
genotype groups in this subset of individuals were 51 (9.9%), 233 (45.2%), and 
231 (44.9%) for the (+/+), (+/-) and (-/-) genotype, respectively, which are not 
substantially different from the MTHFR genotype distribution observed in the 
entire patient group (2=0.137, P=NS). As homocysteine concentrations in the 
different genotype groups showed a skewed distribution (data not shown), 
homocysteine concentrations are expressed in median (range) values. Individuals 
with the homozygous (+/+) genotype have the highest homocysteine 
concentrations and (-/-) individuals have the lowest, whereas heterozygous (+/-) 
individuals have intermediate homocysteine levels.  
 
Table 2. 
Association between MTHFR genotype and fasting serum homocysteine 
concentrations in patients with coronary artery disease 
 
  MTHFR Genotype       Fasting Homocysteine µmol/l 1 
   
  +/+ (n=51)  15.4 (8.7-56.9)2  
  +/- (n=233)  13.4 (7.0-42.9)3  
  -/- (n=231)   12.6 (6.5-30.2) 
 
Homocysteine concentrations are expressed as median values. Range is given in 
parentheses. Homocysteine concentrations are expressed as median values. Range is given 
in parentheses. 1 P<.001 (ANOVA with log-transformed data). 
 2 P<.002 (t test) for +/+ versus +/- and -/- genotypes. 3 P<.05 (t test) for +/- versus -/- 
genotype 
 
Both homozygotes (+/+) and heterozygotes (+/-) have significantly elevated 
homocysteine concentrations compared with (-/-) individuals, demonstrating a 
significant effect of the homozygous (+/+) as well as heterozygous (+/-) 
genotype on homocysteine levels (Table 2). We also assessed the MTHFR 
genotype distribution in different homocysteine strata (Fig 1). The frequency of 
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the homozygous 677CT mutation showed a gradual increase from 4% in the 
lowest homocysteine stratum (homocysteine <10 µmol/L) to 24% in the highest 
stratum (homocysteine >18 µmol/L), again indicating the association between 
homocysteine concentrations and the homozygous (+/+) genotype. 
 
Figure 1 
 
 
Legenda: 
MTHFR genotype distribution in different homocysteine strata. Serum homocysteine 
concentration is expressed in micromoles per liter. In each stratum, the total number of 
individuals is set to 100%. 
 
Thermolabile MTHFR in coronary artery disease 
For a summary estimate of the relative risk of the homozygous (+/+) genotype, 
we performed a meta-analysis of studies reporting data on the MTHFR 
genotypes in patients with coronary artery disease. In this analysis, we confined 
ourselves to case-control studies in which MTHFR genotype distributions among 
coronary artery disease patients as well as control subjects either were given or 
could be calculated from their data. For each study, we calculated odds ratios and 
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95% C.I.s for the (+/+) genotype relative to the (-/-) genotype separately (Fig 2). 
The combination of all studies reported yielded a patient group consisting of 
2476 individuals (299 +/+, 1097 +/-, and 1080 -/-) and a control group of 2481 
individuals (257 +/+, 1090 +/-, and 1134 -/-). From the MTHFR genotype 
distribution in this combined study group, we calculated an odds ratio of 1.22 
(95% CI, 1.01 to 1.47) for the homozygous (+/+) genotype and 1.06 (95% CI, 
0.94 to 1.19) for the heterozygous (+/-) genotype, both relative to the (-/-) 
genotype. When the heterozygotes (+/-) and (-/-) individuals are combined, the 
odds ratio for coronary artery disease among those with the (+/+) genotype was 
1.19 (95% CI, 1.00 to 1.42). 
 
Odds ratios and 95% CIs for CAD associated with the (+/+) genotype relative to the (-/-) 
genotype. Reference number of each study is given in parentheses. 
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Figure 2 
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Discussion 
 
In this study, we showed a correlation between the 677C→T mutation in the 
MTHFR gene and homocysteine concentrations in which homozygous (+/+) and 
even heterozygous (+/-) individuals exhibited significantly elevated 
homocysteine levels compared with (-/-) individuals. Furthermore, by combining 
all previously reported studies, we were able to demonstrate the significance of 
the homozygous (+/+) genotype as a risk factor for coronary artery disease. 
Many studies have explored the relationship between elevated homocysteine 
concentrations and an increased risk for atherosclerotic vascular disease. [2, 3, 
32, 33, 34, 35] Recently, these studies have been summarized in a meta-
analysis,[1] which led to the conclusion that elevations in homocysteine 
concentrations have to be considered as an independent and graded risk factor for 
different categories of arterial occlusive diseases. Several clinical studies 
supported this conclusion by establishing a quantitative relationship between 
coronary occlusion and homocysteine levels.[35, 36] On the basis of a linear 
relationship between homocysteine and the risk of coronary artery disease, 
Boushey et al [1] calculated an odds ratio for coronary artery disease of 1.6 (95% 
CI, 1.4 to 1.7) for a 5 µmol/L increase in homocysteine concentrations. 
Accordingly, a risk of 1.12 can be calculated for a 1 µmol/L increase in 
homocysteine. In our analysis of the association between MTHFR genotype and 
homocysteine concentrations, we observed an increase in median homocysteine 
concentrations of 0.8 µmol/L for heterozygous (+/-) and 2.8 µmol/L for 
homozygous (+/+) individuals relative to (-/-) individuals, which equals a risk for 
coronary artery disease of 1.10 and 1.34 for the heterozygotes (+/-) and 
homozygotes (+/+), respectively, relative to the risk of (-/-) individuals. These 
risk estimates calculated are well in line with the odds ratios for the homozygous 
(+/+) and heterozygous (+/-) genotypes observed in the present study (Table1). 
The frequency of the homozygous (+/+) genotype varies between different 
populations. The effect of this mutation on homocysteine concentrations depends 
on study design, inclusion criteria, ethnic background, age, and vitamin intake of 
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the population. Except for the study of Schmitz et al, [24] all recent studies on 
this MTHFR variant and hyperhomocysteinemia [18, 19, 21, 29, 37, 38] showed 
elevated homocysteine concentrations in homozygous (+/+) individuals. The 
present study supports these observations and indicates again that the 
homozygous (+/+) genotype is associated with elevated homocysteine 
concentrations (Table 2 and Fig 1). Folate status is considered an important 
environmental modulator of homocysteine levels only in homozygous (+/+) 
individuals.[18, 19, 20, 21] The effect of the homozygous (+/+) genotype on 
homocysteine concentrations might therefore differ between separate studies as a 
result of a different intake of folate. A possible adjustment for plasma folate 
could not be performed in this study, because blood folate levels were not 
determined. In the present study, we were also able to demonstrate a statistically 
significant effect of the heterozygous (+/-) genotype on homocysteine 
concentrations. This is in line with the results reported by Harmon et al. ,[38] 
who observed elevated plasma homocysteine concentrations in heterozygous  
(+/-) individuals in the top 50% of the homocysteine distribution. On the basis of 
specific and residual MTHFR activities measured in isolated lymphocytes, this 
observation was not unexpected, because we have shown that heterozygous (+/-) 
individuals have significantly decreased specific and residual MTHFR activities 
compared with nonaffected (-/-) individuals.[18, 20] MTHFR-dependent 
homocysteine remethylation, in which 5-methyltetrahydrofolate (the product of 
the reaction catalyzed by MTHFR) serves as methyl donor, is present in nearly 
every cell of the human body. Therefore, any significantly deleterious effect in 
MTHFR enzyme activity will be reflected in elevation of homocysteine 
concentration in these cells. Previous studies were unable to detect an effect of 
the heterozygous (+/-) genotype on homocysteine concentrations, probably 
because of the relatively limited number of individuals included in those studies. 
Kang et a. [l5] were the first to report on a thermolabile MTHFR variant in two 
patients with coronary artery disease and hyperhomocysteinemia. Subsequent 
studies by the same group [14, 15, 39] showed an association between this 
thermolabile MTHFR and (the severity of) coronary artery disease. In a large 
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study among coronary artery disease patients and healthy control subjects, Kang 
et al.[5] detected thermolabile MTHFR in 36 of 212 cases (17%) versus 10 of 
202 control subjects (5%).[14] In the present study, we observed a much lower 
frequency of the thermolabile (+/+) genotype among Dutch coronary artery 
disease patients and a higher frequency among Dutch population-based control 
subjects. Several possible explanations for this phenomenon should be 
considered. In the study by Kang et al.,[5] the frequency of thermolabile 
MTHFR was assessed biochemically and was not based on genotyping of the 
677C→T mutation. Because of the wide range in MTHFR activities in 
homozygous (+/+) and heterozygous (+/-) individuals,[18, 20] some individuals 
with a biochemically determined thermolabile MTHFR might not have been 
homozygotes (+/+), but heterozygotes (+/-) for the thermolabile allele or carriers 
for other mildly defective MTHFR alleles. In addition, Kang et al. used in their 
studies a control group consisting of healthy controls with no history or clinical 
evidence of arterial occlusive disease. In our study, control subjects were 
recruited from the general population, possibly including individuals with a 
positive history of coronary artery disease, which may dilute an eventual effect 
of the homozygous (+/+) genotype. For a summary estimation of the relative risk 
of the homozygous (+/+) genotype, we analyzed eight different case-control 
studies presenting data on the MTHFR genotype distribution in coronary artery 
disease patients. From these studies,[21, 22, 23, 24, 25, 26, 29] only an Irish 
study [23] observed a significant odds ratio for the homozygous (+/+) genotype 
in coronary artery disease. In all other studies, the odds ratios for the 
homozygous (+/+) genotype were not significantly increased. By combining all 
studies, we were able to calculate a significant odds ratio of 1.22 (95% CI, 1.01 
to 1.47) for the homozygous (+/+) genotype relative to the (-/-) genotype in 
coronary artery disease, an odds ratio comparable to that obtained in the present 
study on the risk of thermolabile MTHFR in REGRESS. This overall result 
indicates that the thermolabile (+/+) genotype itself is a modest but significant 
genetic risk factor for coronary artery disease, a risk that is likely modulated by 
environmental factors, especially folate status.[18, 19, 20, 21] 
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In conclusion, we demonstrated for the first time, that both homozygotes (+/+) 
and heterozygotes (+/-) for the 677C→T mutation in the MTHFR gene have 
significantly elevated homocysteine concentrations relative to (-/-) individuals. 
The odds ratios observed for both (+/+) and (+/-) genotypes for coronary artery 
disease are graded and in concordance 
with the risk calculated from a large quantitative study on homocysteine as a risk 
factor for coronary artery disease. By performing a meta-analysis, we were able 
to show that the homozygous (+/+) genotype is a genetic risk factor for coronary 
artery disease. 
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Introduction 
 
Moderately elevated plasma concentrations of the sulphur amino acid 
homocysteine are associated with increased risk of occlusive cardiovascular 
disease[1]. Elevated plasma total homocysteine concentrations(tHcy) may be 
reduced by supplemental synthetic folate given as folic acid[2], by vitamin B6 
[3] or, in rare cases of vitamin B 12 deficiency, by supplemental vitamin B12[4]. 
Several randomised control trials designed to test the hypothesis that lowering 
plasma tHcy reduces risk of cardiovascular disease are currently underway.[5] 
The present study was designed to identify the minimum dose of folic acid that 
optimally lowers moderately elevated plasma tHcy levels in patients with 
cardiovascular disease. Of secondary importance was the issue of whether 
supplemental vitamin B6 and B12 have significant additional effects in terms of 
reducing plasma tHcy levels. After the present study was initiated, a meta-
analysis of twelve other randomised trials indicated that a 25% reduction in 
plasma tHcy levels could be achieved with daily dietary folic acid supplements 
of between 0.5 and 5mg[6] . Supplemental vitamin B12 (0.5mg mean daily 
intake) reduced tHcy levels by a further seven per cent[6]. However, many of the 
trials were small[3] and involved highly selected,[7] young and healthy subjects 
[8,9]. In those trials involving patients, some had venous thrombosis[10] and in 
those with established vascular disease, the lowest dose of supplemental folic 
acid used was 0.5 mg[6]. 
 
Subjects and Methods 
Subjects 
One hundred and twenty patients from four European centres with both 
diagnostic clinical and investigative evidence of vascular disease were recruited. 
Assuming a 30 % reduction in plasma tHcy concentration, sample size 
calculations indicated that a study of 100 patients would have 80% power at a 
5% level of significance. Patients with clinical and investigative evidence of 
vascular disease were eligible for this study. Exclusion criteria were the use of 
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medication or vitamin preparation involved in homocysteine metabolism. Also, 
patients with systemic illness, chronic alcohol abuse or pregnancy were 
excluded. The duration of the study was three months and entailed a total of five 
visits for each patient. Local ethics committee approval was granted in advance 
of the study. 
 
Methods 
The study involved a factorial design as shown in Table1. This design included 
the incorporation of a vitamin B6 limb and the possibility to study the 
independent effect of vitamin B12 (400µg) on plasma tHcy levels. Within each 
centre, each eligible patient was randomised to one of ten treatment groups, 
resulting in twelve patients in each group. Each of the ten groups was 
characterised by a specific dose of folic acid (200ug, 1mg and 5mg), 
vitamin B12 (400µg), vitamin B6 (30 mg), and placebo, alone, or, in 
combination. All tablets were packaged identically in keeping with the double 
blind nature of the study. Following an initial screening visit, a blood sample for 
plasma tHcy and for methylene tetrahydrofolate reductase (MTHFR) genotyping 
was taken after an overnight fast with the patient seated at 45 degrees for 15 
minutes before sampling at the first visit. This sample was centrifuged and 
stored, protected from light, at -20°. The tHcy sample was repeated at the second 
visit, two weeks later. At this second visit, sufficient medication for five weeks 
was provided but each patient was asked to return in four weeks. Further 
medication was given at the third and fourth visit. The extra seven days' supply 
was provided to allow for subjects who failed to return for review on schedule 
i.e. every four weeks. Two further blood samples were taken and stored for tHcy 
estimations at the third, and eight weeks later, at the fifth visit. Plasma tHcy 
concentrations were analysed centrally in laboratories in Bergen, Norway, while 
the analysis for the MTHFR 677 C→T genotype was carried out in Nijmegen, 
The Netherlands.  
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Table 1 
 
10 Study groups 
 
Placebo     Vitamin B12 400 µg  
Folic acid 200 µg    Folic acid 200 µg +vitamin B12 
Folic acid 1 mg   Folic acid 1 mg + vitamin B12 
Folic acid 5 mg   Folic acid 5 mg + vitamin B12 
Folic acid 1 mg + vit. B6 30 mg Folic acid 1 mg + vitamin B12 + vit. B6 30 mg 
 
 
Statistical Methods 
The initial analysis describes the average percent change in tHcy for various 
treatment arms. Further analysis considered the log transformed tHcy levels. 
Results were obtained using an analysis of covariance that allowed us to describe 
the association between percentage change in tHcy and baseline tHcy having 
adjusted for treatment regimen and similarly to describe the variation in 
percentage change in tHcy at visit three/five and treatment regimen (folic acid, 
vitamin B6 or vitamin B12) having adjusted for baseline tHcy levels. Average 
tHcy levels at different time points were compared using a paired t-test of log 
transformed tHcy concentration. 
 
Results 
 
Using log transformed data, no significant difference in tHcy concentrations 
between the first and second visits (p=0.38) was found and baseline tHcy was 
defined as the average of the first two readings. There was a significant decrease 
in tHcy concentration between the baseline measurement and the third visit 
(p<0.0001) and a smaller, although still statistically significant decrease, 
between the third and last tHcy measurement (p=0.02). Tables 2 and 3 indicate 
the mean proportional change in tHcy concentration according to treatment arm. 
For those groups receiving folic acid, there was a significant difference in tHcy 
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concentration between the groups at visit 3 (p=0.004) but not at visit 5 
(p==0.31). The effect of vitamin B12 in terms of proportional tHcy reduction 
was not significant at visit three (p=0.34) but was significant by the time of the 
last visit (p=0.05).  
 
Table 2 
 
Mean change (%) in total plasma homocysteine at visit three 
 
 vitamin B12 400µg no vitamin B12   combined groups 
 
Placebo -1.0 % -1.5 % -1.3% (95% CI: -3.7- 1.1) 
Folic acid 200 µg -15.4 % -9.6% -12.5% (95% CI: -14.6 - -10.4) 
Folic acid 1 mg -22.7% -20.0% -22.4% (95% CI: -23.3- --20.4) 
Folic acid 5 mg -24.9% -23.6% -24.2% (95% CI: -26.4- -22.0)  
Folic acid 1 mg/ -23.8% -22.7% -23.3% (95% CI: -21.3- --25.3) 
Vitamin B6 30 mg 
 
 
 
Table 3 
 
Mean change (%) in total plasma homocysteine at visit five 
 
 vitamin B12 400µg no vitamin B12   combined groups 
 
Placebo -5.8 % 2.1 % -1.9% (95% CI: -4.0-  1.2) 
Folic acid 200 µg -23.7 % 16.1% -20.0% (95% CI: -22.7- -17.3) 
Folic acid 1 mg -22.6% -19.1% -22.5% (95% CI: -24.5- -20.3) 
Folic acid 5 mg -26.5% -25.0% -25.7% (95% CI: -28.1- -23.3)  
Folic acid 1 mg/ -26.8% -21.5% -24.2% (95% CI: -26.2- -22.0) 
Vitamin B6 30 mg 
 
 
 
One half of the patients who were randomised to receive l mg folic acid also 
received 30mg of vitamin B6. An ANCOVA that included baseline log tHcy, 
folic acid (4 categories), Vitamin B12 (2 categories) and B6 (2 categories), 
revealed no significant difference in the average percent change in tHcy 
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concentration between those who received vitamin B6 given at 30mg daily and 
those who did not. Since vitamin B6 was given to those patients already 
receiving l mg of folic acid, the possibility that vitamin B6 has an effect on tHcy 
concentrations when given with other doses of folic acid cannot be excluded. 
Vitamin B6 was not included in subsequent analysis. There was a significant 
association between baseline tHcy and proportional change in tHcy levels at visit 
three (p<0.0001) and at visits five (p=0.02) (Table 4). Increased baseline tHcy 
concentrations were associated with a more rapid proportional decline in tHcy 
concentration.  
 
Table 4 
 
Predicted change (%) in tHcy at visit 3 and 5 (mean change and 95% CI) 
Results adjusted for baseline total plasma homocysteine and vitamin B12 treatment 
 
 Combined B12 arms at visit 3 Combined B12 arms at visit 5 
  (mean and 95% CI)  (mean and 95% CI) 
 
Placebo  -2.5% (95% CI –8.5- 3.9) -1.1% (95% CI: -8.3-  6.5) 
Folic acid 200 µg -13.6 % (95%CI –18.9- --7.9) -19.5% (95% CI: -25.4- -13.1) 
Folic acid 1 mg -24.0% (95%CI-27.7- -20.1) -22.5% (95% CI: -26.9- -17.8) 
Folic acid 5 mg -26.1% (95% CI-30.8- --21.1) -25.7% (95% CI: -31.3- -19.6)  
 
 
 
Among those receiving folic acid there was a significant association between 
folic acid dose and the proportional decline in tHcy at visit three (p<0.0001), but 
not visit five (p=0.22). The lowest dose of folic acid (200µg) achieved a 
reduction in tHcy concentration at visit five which was not significantly different 
from that achieved by the highest dose at the third visit: 26.1(95CI: 21.1 -30.8) 
compared to 19.5(95CI: 13.0 - 25.4). There was a significant association between 
vitamin B12 and the additional proportional reduction at the fifth visit 7.0%  
(95C.l.: 0.0 -13.0) but not at week three (95 CI:-3 -13.0) Because the methylene 
tetrahydrofolate reductase 677 C→T mutation is one of the factors responsible 
for the interindividual variation in the response to tHcy lowering therapy the 
frequency of this genotype was estimated. In total, twelve homozygotes were 
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identified (8.6%) and, at most, two homozygotes for the genotype were found in 
4 treatment groups. 
 
Discussion 
Plasma total homocysteine (tHcy) concentration is inversely related to plasma 
folate concentration [11,13] and to dietary intake of folate and vitamin B6 [12]. 
This inverse relationship is weaker for vitamin B6 and vitamin B12 levels [12].  
The lowest plasma tHcy concentration is associated with a folate intake of 
approximately 400µg/day [12] but recent data suggest that the intake among 
adults age 65 years and older is actually between 200 and 250 µg/day [14,15]. 
The present study indicates that, among patients with established cardiovascular 
disease, daily exposure to the lowest dose of supplemental folic acid (200µg) for 
12 weeks achieves a reduction in plasma tHcy that is not significantly different 
from that achieved with 1mg of folic acid for four weeks. A daily supplemental 
dose of 200µg synthetic folic acid with 400 µg vitamin B12 is sufficient to 
reduce plasma tHcy concentrations by approximately 20 per cent in this 
population with established cardiovascular disease and high baseline tHcy 
concentrations. This suggests that among typical patients with atherosclerotic 
vascular disease, it is possible to saturate folate stores with daily low-dose folic 
acid and vitamin B12 supplements. Providing higher daily doses achieves little 
further reduction in plasma tHcy concentration. The 30mg dose of vitamin B6 
used in this study had no significant effect on elevated fasting tHcy 
concentration. This does not exclude an effect at higher doses and does not 
discount the possible value of reducing post-load tHcy concentrations (not 
measured in this study) with vitamin B6 [16]. In addition, there is evidence that 
vitamin B6 deficiency is related to vascular disease risk independently of tHcy 
concentration [17,18]. One other general practice-based study among healthy 
patients indicates that an additional folate intake of 200 µg/day reduces plasma 
tHcy by 10% [19].  In one further study, plasma tHcy was reduced by 20% with 
an additional 350 µg/day of dietary folic acid [20]. The reduction in plasma tHcy 
concentration achieved by a 200 µg daily dose of synthetic folic acid is important 
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for three reasons. Firstly, achieving maximal tHcy reduction with the lowest 
effective dose of folic acid may reduce the risk of potential adverse effects 
resulting from higher intakes of folic acid [21]. Secondly, a daily folic acid 
increment of 200µg approximates to what is achievable by optimal dietary means 
alone [5]. However, a recent study illustrates the well-described reduced 
bioavailability of dietary folate [22] and suggests that the most effective means 
of lowering tHcy concentration is with fortified foods or synthetic folic acid 
supplements [23]. An approximate 300 µg increase in daily folic acid from 
folate-fortified cereals resulted in a plasma tHcy reduction of 24 per cent. 
However, the consumption of folate-rich foods that achieved a daily folate 
increase of over 400 µg resulted in a nine per cent reduction in plasma tHcy 
concentrations. Folic acid supplements did not achieve a tHcy lowering effect in 
excess of that achieved by folic acid fortified cereals [23]. Thirdly, a 20 per cent 
reduction in plasma tHcy concentration among populations with a mean level of 
12 µmol/L might result in a cardiovascular risk reduction of 25 percent  [24]. By 
a variety of methods, an increased intake of folic acid would prevent between 
four and 14 per cent of coronary heart disease deaths in the United States 
population [23]. Enrichment of flour with folic acid has been undertaken in the 
United States since 1998 and one early report suggests a significant reduction in 
the prevalence of low folate states [25]. Whether or not this increase in folate 
intake will reduce the risk of first occurrence of cardiovascular disease in the 
entire population remains to be seen. The present study suggests that potentially 
significant benefits might be achievable with low dose folic acid 
supplementation in populations of patients with established cardiovascular 
disease.  
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Introduction 
 
 Atherosclerosis remains the leading cause of death in Western society. 
Established risk factors as hypercholesterolaemia, hypertension, diabetes 
mellitus and smoking cannot fully explain the great number of patients with 
cardiovascular disease. Different inborn errors in methionine metabolism lead to 
severe hyperhomocysteinemia or homocystinuria. Such patients suffer from 
serious vascular disease[1]. These observations led to the hypothesis that 
homocysteine is a toxic agent for the vascular system.  Since then a large number 
of epidemiological studies have been published on the relationship between mild 
hyperhomocysteinemia and coronary artery disease. It has now been 
demonstrated that an elevated fasting total plasma homocysteine level (tHcy) in 
patients with vascular disease is associated with increased cardiovascular 
mortality[2,3]. In a recent meta-analysis elevated homocysteine is also 
considered a modest independent predictor of coronary artery disease in healthy 
populations [4]. The mechanism responsible for the toxic effect of homocysteine 
remains however unclear. Several studies demonstrated a correlation between 
tHcy levels and the extent and severity of coronary artery disease[5,6,7]. 
However these results are not unequivocal [2,8]. None of these studies used 
quantitative coronary angiography (QCA) for the evaluation of the extent and 
severity of coronary artery disease. Previous angiographic follow up studies 
using quantitative coronary angiography could not demonstrate a convincing 
relationship between classic risk factors as smoking, blood pressure, total 
cholesterol, LDL-cholesterol and HDL- cholesterol and progression of 
atherosclerosis[9,10]. The effects of elevated plasma homocysteine levels on 
progression of atherosclerosis are unclear.  Aim of  this study was to evaluate the 
relationship of tHcy with the extent of coronary artery disease and the 
relationship of tHcy with anatomical changes in the coronary vessels in patients 
with symptomatic coronary artery disease. 
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Methods 
Study population: 
The study population was recruited from the Regression Growth Evaluation 
Statin Study (REGRESS) population, a double blind, placebo controlled, 
multicenter study conducted in the Netherlands to assess the effects of 2 years of 
treatment with the HMG-CoA reductase inhibitor pravastatin on progression and 
regression of angiographically documented coronary atherosclerosis11. All male 
patients, < 70 years old, who were scheduled to undergo coronary angiography 
for clinical reasons were eligible for participation in this study.  If the total 
cholesterol value was between 4.0 mmol/l and 8.0 mmol/ and the coronary 
angiography showed at least one lesion that narrowed the lumen in a coronary 
vessel by  ≥50% the patients were qualified for this study. Patients with previous 
PTCA and CABG, patients with congestive heart failure, pacemaker implant and 
cardiac disease requiring valve replacement were excluded.  Also, patients with 
diabetes mellitus, uncorrected hypo- or hyperthyroidism, renal disease 
(creatinine ≥ 150 µmol/l), hepato-biliary or pancreatic disease were excluded. 
Between December 1989 and December 1991, 1068 patients were initially 
screened before participation in the REGRESS study. Finally 885 patients were 
randomized. Patients received pravastatin, 40 mg once daily or placebo and 
during the treatment period patients were asked to stay on a stable diet. Of 606 
patients a EDTA-plasma sample was available for tHcy determination. 
 
Clinical events 
The following clinical events were analyzed: Myocardial infarction (fatal and 
nonfatal). To establish a diagnosis of a new myocardial infarction two of the 
three following criteria had to be met: characteristic angina> 30 minutes, new 
ischemic Q waves or ST-T wave changes in the ECG and elevation of creatine-
kinase MB fraction to > 3 times the upper limit of normal.  Coronary heart 
disease death : no known non-athererosclerotic cause and presence of cardiac 
symptoms within 72 hours of death. Non-scheduled PTCA or CABG. Stroke and 
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transient ischemic attack: motor or sensory dysfunction more (stroke) or less 
(TIA) than 24 hours. 
 
Quantitative coronary angiography 
The influence of tHcy on the extent and progression of atherosclerosis was 
assessed using quantitative coronary angiography at baseline and after two years. 
For quantitative coronary angiography the coronary vessels were divided in 13 
segments according to the American Heart Association classification.[12] Mean 
Segment Diameter (MSD) and Minimum Obstruction Diameter (MOD) of all 
segments were measured using quantitative coronary angiography. MSD reflects 
diffuse changes in coronary segments or arteries while MOD reflects the degree 
of narrowing of an atherosclerotic lesion.  A stenosis of ≥ 50% was considered 
significant. Patients with a stenosis more than 50% in two vessels or more are 
considered to have multivessel disease. Because PTCA and CABG procedures 
may influence progression considerably we excluded in the primary analysis 
lesions and segments modified or conceivably modified by PTCA or CABG. In 
addition, patients were categorized with regard to MOD and clinical events as 
progressors, stable patients and regressors. Progressors are patients with at least 
one lesion worsening by ≥0.4 mm or the development of a new lesion that 
reduces the lumen diameter by ≥ 0.4 mm. If a patient had suffered a clinical 
cardiovascular event, he was considered to be a progressor, irrespective of the 
angiographic outcome. 
 
Biochemical Measurements 
After an overnight fasting an EDTA-plasma sample of venous blood was drawn 
from the patients. Plasma total homocysteine was measured by high performance 
liquid chromatography[13]. Patients were divided in quartiles according to their 
homocysteine level. For calculation of the relative risk of progression of 
atherosclerosis in hyperhomocysteinemia, we considered a tHcY of ≥ 15 µmol/l 
as abnormal. Lipid laboratory tests were carried out at the Lipid Reference 
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Laboratory and comprised total cholesterol, HDL- cholesterol and triglycerides. 
LDL-cholesterol was calculated according to the Friedewald formula. 
 
Statistical analysis: 
Analysis of data was performed using one-way analysis of variance or Chi-
Square test where appropriate. Differences between homocysteine-quartile 
groups were tested for trend. Spearman rank correlations were reported for the 
association between homocysteine levels and MSD and MOD at baseline and for 
the association between change in MOD, MSD and percent stenosis during 
follow-up. Angiographic changes were calculated using covariance analysis with 
baseline levels as covariate and homocysteine levels as factor. Cumulative event 
incidence were calculated with Kaplan-Meier curves, and compared using the 
log-rank test.  
 
Results 
Of the 885 patients included in the REGRESS study, homocysteine levels were 
available in 606 patients. Angiographic follow-up was available in 438 patients. 
Baseline characteristics of these groups are presented in table 1. Patients not 
included in this study had slightly more often a history of hypertension (33%) 
than patients included in the study (26%) (p=0.027). Patients in whom a plasma 
homocysteine sample was available and who had a second angiography,  total 
cholesterol (5.96 mmol/l SD 0.87) was slightly lower compared to the patients 
initially included in REGRESS (6.04 mmol/l SD 0.86) p<0.05. During follow-up 
HDL-cholesterol increased significantly more in the 606 patients eligible for this 
study compared to patients in whom no homocysteine sample was available. 
Otherwise there were no significant nor large differences in baseline 
characteristics. 
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Table 1 
Baseline characteristics 
 
 All Patients with Patients with p value† 
 Patients homocysteine homocysteine  
 sample  sample   
and second  
 angiography    
 (N=885)  (n=606) (n=438) p1‡ p2§ 
 
 
Age (years)  56.2 (8)*  56.4 (8) 55.6 (8.0) 0.44 0.53 
Body Mass Index  26.0 (2.7)  25.9 (2.6) 25.9 (2.7) 0.10 0.15 
Systolic BP (mmHg)  135 (19)  135(18) 134 (18) 0.97 0.79 
Diastolic BP (mmHg)  81 (10)  81 (10) 82 (10) 0.72 0.79 
Ejection fraction (%)  70 (13)  70 (12) 71 (12) 0.73 0.84 
Baseline MOD (mm)  1.76 (0.35) 1.75 (0.35) 1.80 (033) 0.28 0.98 
Baseline MSD (mm) 2.74 (0.37) 2.73 (0.38) 2.76 (0.37) 0.18 0.53 
Total cholesterol (mmol/l) 6.04 (0.86) 6.00 (0.86) 5.96 (0.87) 0.07 0.017 
HDL-cholesterol(mmol/l) 0.93 (0.23) 0.92 (0.22) 0.93 (0.22) 0.27 0.37 
LDL-cholesterol(mmol/l) 4.31 (0.78) 4.28 (0.78) 4.25 (0.78) 0.23 0.10 
Triglycerides(mmol/l) 1.78 (0.76) 1.76 (0.76) 1.73 (0.75) 0.29 0.14 
Creatinine(µmol/l) 96.4 (15.7) 96.8 (16.5) 96.9 (16.8) 0.30 0.30 
Smoking (%) 27.7%  26.2% 26.9%  0.09  0.17 
History of hypertension (%)27.8%  25.6% 26.9%  0.027   0 .09 
Familial heart disease (%) 48.6%  48.3% 47.4%             0.76  0.59 
History of myocardial (%) 47.4%  46.4%  45.3%  0.35  0.24 
infarction 
 
*Values are reported as a mean with SD between brackets 
† P-value of one way analysis of variance, or chi-square test where appropriate. 
‡ p1 for the difference between all patients and patients in whom a plasma homocysteine 
sample was available,  
§ p 2 for the difference between all patients and patients with in whom a plasma 
homocysteine sample was available and also a second angiography. 
 
 
Of the 606 patients included in this study mean age was 56.6 years (SD 8.0).  
Median tHcy was 13.2 µmol/l with a range of 6.5-67.7 µmol/l. Patients were 
divided in quartiles according to their homocysteine level. The quartiles ranged 
from 6.5 µmol/l to 11.3 µmol/l (1), 11.4 µmol/l-13.2 µmol/l (2), 13.5 µmol/l-
15.5 µmol/l (3) and 15.6 µmol/l-67.7 µmol/l (4). Baseline characteristics of the 
four quartiles are shown in table 2.  As expected homocysteine levels are 
correlated with age (p<0.001). Triglycerides between quartiles differed 
significantly (p=0.021). No other differences between quartiles existed.  Table 3 
shows the extent of cardiovascular disease of the four quartiles. When 
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considering a stenosis of ≥ 50% significant, approximately 60% of the patients 
had multivessel disease at baseline. The number of vessels involved in the  
Table 2 
 
Baseline characteristics patients with homocysteine sample at baseline  
  
Homocysteine levels  
in quartiles (µmol/l) 6.5-11.3 11.4-13.2 13.3-15.5 15.6-67.7 p value† 
 (n=152) (n=153) (n=154) (n=147) 
 
Age (years)  53.5 (7.6)* 55.7 (7.5) 58.1 (8.0) 58.4 (8.1) <0.001  
BMI  26.0 (2.5) 25.8 (2.4) 26.0 (3.0) 25.8 (2.5) 0.92 
Systolic BP (mmHg) 133 (19) 135 (19) 137  (19) 134 (16) 0.24 
Diastolic BP (mmHg) 80 (11)  81 (9) 81  (10) 82 (10) 0.23 
Ejection fraction (%) 70 (12)  70 (12) 71 (12) 70 (13) 0.81 
Total cholesterol (mmol/l) 5.96 (0.8) 6.08 (0.8) 5.90 (0.9) 6.06 (0.9) 0.67 
HDL-cholesterol (mmol/l) 0.93 (0.24) 0.95 (0.19) 0.91 (0.22) 0.90 (0.22) 0.10 
LDL-cholesterol (mmol/l) 4.25 (0.8) 4.38 (0.7) 4.18 (0.8) 4.32 (0.86) 0.97 
Triglycerides (mmol/l) 1.74 (0.8) 1.64 (0.7) 1.78 (0.7) 1.89 (0.8) 0.021 
Smoking (%) 28.9%  23.5% 22.1%  30.6%  0.87 
History of hypertension(%) 21.7%  21.7% 33.8%  25.2%  0.16 
Familial heart disease(%) 48.7%  48.4% 46.8%  49.7%  0.97 
History of myocardial(%) 45.4%  43.8%  49.4%  46.9%  0.66 
infarction 
 
*Values are reported as a mean with SD between brackets 
† P-value of one way analysis of variance, or chi-square test where appropriate 
 
 
 
 
Table 3 
 
Extent of  coronary artery disease in 606 patients  
    
Homocysteine levels  
in quartiles (µmol/l) 6.5-11.3 11.4-13.2 13.3-15.5 15.6-67.7 p value* 
 (n=152) (n=153) (n=154) (n=147) 
 
Extent of coronary artery disease   0.24 
1 vessel  66 (43.7%) 56 (36.6%) 64 (41.6%) 53 (36.6%)  
2 vessels  50 (33.1%) 58 (37.9%) 51 (33.1%) 49 (36.6%) 
3 vessels  35 (23.2%) 39 (25.5%) 39 (25.3%) 43 (29.7%) 
 
* exact chi-square test for linear trend 
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atherosclerotic process did not differ among quartiles (p=0.24). When 
considering a tHcY of ≥ 15 µmol/l as abnormal, the relative risk (RR) for 
patients with tHcY ≥15 µmol/l to have multivessel disease is 1.21, p=0.54, 
(95%CI: 0.78-1.58) .  
Table 4 shows the clinical events of the patients according to their homocysteine 
levels. The number of cardiovascular deaths is less than 1% irrespective of 
homocysteine levels. Only 92 patients suffered from a cardiovascular event 
during follow up. The number of events did not correlate with tHcy quartiles 
(p=0.97). Also, when we compared the number of events in the placebo and 
pravastatin groups separately no differences were found concerning the number 
of events in the four homocysteine quartiles (p=0.87 and p=0.60 respectively). 
The RR for patients with tHcY of ≥15 µmol/l to suffer a cardiovascular event is 
1.01, (95% CI: 0.62-1.62) p=0.96. 
 
 
Table 4 
 
clinical events      
 
Homocysteine levels  
in quartiles (µmol/l) 6.5-11.3 11.4-13.2 13.3-15.5  15.6-67.7 p value * 
 (n=152) (n=153) (n=154)  (n=147) 
 
 
non-fatal myocardial infarction 2 1  3 3 0.46 
fatal myocardial infarction 0 0  0 1 0.25 
cardiovascular death 1 1  1 1 0.99 
death unknown cause 1 1  2 0 0.83 
non-scheduled PTCA 13 9  13 8 0.48 
non-scheduled CABG 5 10  12 6 0.69 
Stroke 1 0  0 1 0.99 
Non vascular death 2 1  0 1 0.52 
 
* exact chi-square test for linear trend 
 
Of 606 patients enrolled in this study, a second coronary angiography was 
available in 438 patients. Complete angiographic data of the remaining 168 
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patients were not available for analysis due to missing of a pair of matching 
angiographies (n=77) or due to the fact that all coronary segments were 
considered to be influenced by a performed PTCA or CABG(n=91). In the first 
homocysteine quartile 38 (25%) patients had no second angiography, in the 
second quartile 32 (21%), in the third 37 (24%), and in the fourth quartile 51 
(35%). This difference between quartiles was statistically significant (p=0.048). 
During follow-up lipid values in the placebo group remained unchanged. Lipid 
values in the pravastatin group decreased significantly. Other baseline risk 
factors did not change significantly during follow-up. Changes in lipid values 
during follow-up differed not between the patients with and without a second 
angiography. Changes in MSD and MOD were not associated with different 
quartiles of homocysteine in all patients (p=0.39, p=0.86 respectively) (Table 5).  
 
 
Table 5 
 
 
Angiographic changes during follow-up     
 
Homocysteine levels  
in quartiles (µmol/l) 6.5-11.3  11.4-13.2 13.3-15.5 15.6-67.7 p value†  
      
All patients (n=438) 
Change MSD, mm  -0.06 (0.18) -0.09 (0.20) -0.10 (0.20) -0.09 (0.20) 0.18 
Change MOD, mm  -0.11 (0.44) -0.10 (0.22) -0.12 (0.27) -0.09 (0.21) 0.68 
 
Placebo group (n=216) 
Change MSD, mm  -0.06 (0.19) -0.13 (0.21) -0.14 (0.23) -0.13 (0.20) 0.13 
Change MOD, mm  -0.07 (0.16) -0.14 (0.23) -0.15 (0.26) -0.11 (0.20) 0.30 
 
Pravastatin group (n=219) 
Change MSD, mm  -0.05 (0.18) -0.05 (0.18) -0.06 (0.16) -0.05 (0.21) 0.94 
Change MOD, mm  -0.15 (0.57) -0.06 (0.20) -0.08 (0.28) -0.06 (0.22) 0.25 
 
*Values are reported as a mean with SD between brackets  
† p-value of covariance analysis with baseline levels as covariate, and homocysteine 
quartile as factor testing the trend in the quartiles. 
 
 
The mean change in MSD was -0.08 mm (SD 0.19) for tHcy < 15 µmol/l 
compared to –0.10 mm (SD 0.20) for tHcY ≥15 µmol/l, p=0.43, mean difference 
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0.017 mm (95%CI: -0.025 - 0.054). The mean change in MOD was -0.11 mm 
(SD 0.33) for tHcy < 15 µmol/l compared to –0.10 mm (SD 0.21) for tHcY ≥15 
µmol/l,  p=0.84, mean difference 0.006 (95%CI: -0.057 -  0.070).  
Change in MSD, change in MOD and change of percent stenosis did not 
correlate with tHcy (Spearman rank correlation factor r=0.05, r=0.01, r=0.02 
respectively). 282 patients out of 438  patients were progressors (64%), 
progression was not related to quartiles of tHcy (p=0.37). The relative risk of 
progression for patients with tHcY≥15 µmol/l is 1.14 (95%CI 0.81-1.58), 
p=0.77. When we compared the effects of tHcy levels for the placebo group and 
the pravastatin treated group separately, again no differences were found.  The 
relative risk was also calculated for baseline total cholesterol ≥6.0 mmol/l (RR 
1.67, 95% CI 1.15-2.43, p=0.007), LDL cholesterol ≥ 4.3 mmol/l RR 1.38, 95% 
CI 0.95-2.01, p=0.11), HDL cholesterol < 0.9 mmol/l (RR 1.15 95% CI 0.79-
1.67, p=0.43), triglycerides ≥ 1.6 mmol/l (RR 1.13, 95% CI 0.78-1.64, p=0.48), 
hypertension (yes/no) (RR 0.98 95% CI 0.64-1.5, p=0.73) and smoking (yes/no) 
(RR 1.16 95% CI 0.76-1.76, p=0.11).  
 
Discussion 
This is one of the largest prospective study on the relationship between tHcy 
levels and progression of atherosclerosis in coronary vessels in patients with 
symptomatic coronary artery disease. This study showed no association between 
tHcy and the extent of coronary atherosclerosis and no significant correlation 
between tHcy levels and progression of atherosclerosis. In this study only 
baseline total cholesterol was significantly related to progression of 
atherosclerosis. In REGRESS none of the other clinical baseline risk factors in 
patients were related to progression. In contrast to our findings there is strong 
evidence in both experimental and clinical investigations that 
hyperhomocysteinemia is associated to clinical vascular disease. There is 
growing evidence both in vitro and in vivo studies that homocysteine causes 
endothelial injury and therefore may have an adverse impact on anti-thrombotic 
and vasomotor effects of the vessel wall [14,15].  Recently we could demonstrate 
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that homocysteine-lowering treatment improved coronary endothelial function in 
hyperhomocysteinemic patients[16].  
 
Homocysteine in relationship to cardiovascular events:  
The number of  cardiovascular events during a relative short period of follow-up 
was too low to draw conclusions about a possible relationship between elevated 
tHcY and cardiovascular events. Based on the data of this study the odds ratio 
estimating the risk to suffer a vascular event in patients with a homocysteine 
level of ≥ 15 µmol/l  was only 1.01 (95%CI 0.62-1.62).  These data are 
conflicting with the data of Nygård et al [2] and Taylor et al.[3] who showed, 
that tHcy is related to cardiovascular events and mortality. A possible bias in 
Nygårds study was that patients with a low ejection fraction were responsible for 
more than 50% of the mortality suggesting that the lower ejection fraction, at 
least in part, may be responsible for this excess in mortality. Patients in our study 
were relatively younger, and patients above 70 years excluded. Also, patients 
suffering from diabetes mellitus were excluded. Some of these differences in 
may explain the fact that the number of events in our study was low, irrespective 
of the patients’ homocysteine levels. In our study, a significantly higher number 
of patients in the quartile with the highest homocysteine levels had no second 
angiography. This aspect could bias the results of our study although the number 
of clinical events differed not among quartiles. Since cardiovascular events are 
correlated with changes in serial quantitative coronary angiography, it seems less 
likely that this aspect has important drawbacks on our study[17] .  
 
Homocysteine and coronary atherosclerosis:  
Data upon possible relation between homocysteine and the extent of coronary 
artery disease are not unequivocal. Some investigators found a graded effect of 
homocysteine levels on coronary artery disease [5,6,7] while other investigators 
found no relation [8]. This may be explained by the fact that the investigators 
used different methods to assess the extent of coronary artery disease, none of 
them based on quantitative coronary angiography. It is well known that visual 
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estimation of the degree of coronary stenosis is subject to significant operator 
variability[18]. The use of quantitative coronary angiography has several 
drawbacks when we are investigating the effect of homocysteine on progression 
of coronary atherosclerosis. Due to a lack of follow-up in a substantial portion of 
the patients initially included, partly because of a clinical event,  the effects of 
homocysteine on change in MSD and MOD can be underestimated in this study. 
In this study, in the group of patients with the highest plasma homocysteine 
levels, the number of patients without a second angiography is significantly 
higher. However, since the correlation coefficients for the association between 
tHcY levels and change in MOD or MSD show no association it seems  less 
likely that our results have been biased by the lack of follow up in a part of this 
group.  It is also possible that a follow up period of two years for detection of 
atherosclerotic changes related to homocysteine is too short. Observational 
studies with repeated coronary angiography have shown that mainly the time 
between two consecutive angiographies, and not baseline variables like lipid 
levels, was associated with progression of atherosclerotic disease [9,10,19,20] 
 
Study limitations 
The results of our study, as in all angiographic studies, can be biased since 
follow-up angiography was not available in all patients who were initially 
included in this study. It is possible that changes in risk factors during follow-up 
influenced the results of our study. However lipid values in the placebo group 
and smoking habits in both groups did not change significantly. It seems less 
likely that changes in other risk factors have biased our findings. Although the 
number of patients included in this angiographic study is high, a two year follow 
up to investigate the effect of homocysteine on progression of atherosclerosis is 
probably too short. The number of events is too low to draw conclusions upon a 
possible relationship between elevated plasma homocysteine and cardiovascular 
events. We have no data on folic acid and vitamin B12 levels of the patients 
included in this study. However, irrespective of the cause of 
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hyperhomocysteinemia in the study patients the effect of homocysteine on 
vascular disease remains probably the same.  
 
Conclusion 
The findings in this prospective angiographic study suggest that tHcy is not 
associated with angiographic progression of atherosclerosis nor with the extent 
of coronary artery disease. Since elevated plasma homocysteine levels are clearly 
associated with an increased cardiovascular risk, the mechanism responsible for 
this increased risk is remains unclear. 
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Introduction 
 
Hyperhomocysteinemia is a strong and graded risk factor for premature 
cardiovascular disease.  Until now more than 80 studies have been published 
upon the association between homocysteine and vascular disease[1]. The 
pathophysiological mechanisms responsible for this increased risk remain 
unclear. Evidence is accumulating that elevated homocysteine causes endothelial 
dysfunction[2]. Endothelial dysfunction is a key mechanism in the current 
hypothesis of atherothrombosis. Recently we could demonstrate that 
homocysteine –lowering treatment in hyperhomocysteinemic patients improves 
coronary endothelial function[3] . Most but not all human studies show a 
relationship between increased total plasma homocysteine levels (tHcY) and 
impaired endothelial function using a fore-arm model [2]. Although factors 
known to impair endothelial function in the coronary circulation also are 
associated with impaired flow mediated dilatation in the brachial artery[4,5] , the 
direct relevance of this technique for long term cardiovascular risk is uncertain. 
Aim of this study was to investigate the relationship between elevated tHcY and 
acetylcholine-induced changes in coronary blood flow (CBF) in non-stenotic 
coronary vessels in patients with coronary artery disease. 
 
 
Methods 
 
Patient selection 
Patients with objectively confirmed ischemic heart disease who were referred for 
elective PTCA to our catheterization laboratory were eligible for this study. 
Endpoints were acetylcholine-induced changes in endothelium dependent 
coronary blood flow. Inclusion criteria were age between 18 and 70 years and at 
least one coronary vessel without a significant stenosis (stenosis < 20%) . We 
considered a tHcY of ≥ 15 µmol/l as abnormal. Patient groups were matched for 
gender, smoking habits, history of hypertension, family history of vascular 
Hyperhomocysteinemia and endothelial dysfunction 
 98
disease, lipid levels and actual medication. Patients who used medication or 
vitamins involved in homocysteine metabolism were excluded from this study as 
were patients with diabetes mellitus and patients with uncontrolled hypertension. 
Patients with renal failure reflected as a creatinine level of more than 150 µg /l or 
serious liver failure were also excluded. The ethical committee of our institution 
approved the protocol. Informed consent was obtained in all patients.  
 
Coronary angiography 
Long acting nitrates were withdrawn 24 hours before the procedure and replaced 
by short acting nitrates if necessary. After the performance of the elective PTCA 
a new guiding catheter 7 Fr. (Medtronic) was placed in a non-dilated coronary 
artery without a significant stenosis (< 20%). A Doppler guide wire (0.014 inch 
diameter), (Flowire, Endosonics Incorporated) within a 2.2 F coronary infusion 
catheter (Medtronic) was advanced in the vessel of interest just distal to a 
landmark of a proximal epicardial segment with a diameter of at least 2.0 mm. 
Assessment of endothelium dependent vasodilatation and coronary flow was 
performed by subsequent selective infusions of acetylcholine with a total amount 
of 10-8 M, 10-7 M, 10-6M respectively. Acetylcholine was dissolved in NaCl 0.9% 
and infused with a Terumo® pump at a rate of 2 ml/min during 3 minutes. For 
assessment of endothelium independent vasodilatation nitroglycerin 200 µg was 
then injected in the coronary vessel as a bolus. Before infusion of acetylcholine 
baseline angiography was performed using Hexabrix® with biplane technique. 
Then acetylcholine infusion started. After each infusion of acetylcholine a 
coronary angiography followed.  
 
Assessment of coronary blood flow 
Doppler flow velocity spectra were analyzed to determine time-averaged peak 
velocity.  Coronary blood flow (CBF), assuming laminar flow, is the cross 
sectional area times average peak velocity times 0.5 [6]. Endothelium-dependent 
coronary flow reserve is calculated as percent change in CBF in response to 
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acetylcholine. Normal coronary endothelium dependent function is defined as an 
increase of CBF of 50% or more [7].  
 
Quantitative coronary angiography 
Analysis of baseline and follow-up angiographies was performed using the 
CAAS II QCA software (Pie Medical, Maastricht, The Netherlands). Analysis of 
MOD and MSD started at the proximal landmark of the defined epicardial 
segment and continued until the second important landmark of the segment.  
For assessment of CBF the cross sectional area was measured over 5 mm in the 
segment 5 mm to 10 mm distal to the tip of the Flowire.  
 
Laboratory measurements 
After an overnight fast a sample of venous blood was drawn on EDTA from the 
patients and put on ice immediately. Plasma total homocysteine was measured by 
high performance liquid chromatography[8]. Also samples for vitamin and lipid 
analysis were analyzed.  
 
Statistics 
A sample size of 18 subjects would be required to detect an improvement in CBF 
of 100% (SD 50%), with 90% power at a 0.05 significance level. Data are 
expressed as mean ± standard deviation (SD). Analysis of data was performed 
using one-way analysis of variance (ANOVA) or chi-square test where 
appropriate. Response differences in CBF between groups following two 
subsequent amounts of acetylcholine infusion (10-7M and 10-6M) were compared 
using a multivariate repeated measures model (General Linear Model, SPSS 
10.1). Spearman rank correlation coefficients are given for the relationship 
between tHcY and maximal change in CBF. 
 
Results 
The study population eligible for this study consisted of 38 patients, 34 men and 
4 women. Mean age was 54.4 years (SD 7.0) and mean tHcY was 14.2 (SD 4.2).  
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19 patients had a tHcY of < 15 µmol/l (mean tHcY: 10.5 µmol/l (SD 2.1) and 19 
patients had a tHcY of ≥15 µmol/l (mean tHcY: 17.9 µmol/l, (SD 1.7). Baseline 
characteristics of the two groups are shown in table 1. Folic acid levels were 
significantly higher in patients with low tHcY levels, 13.6 nmol/l (SD 1.9) 
compared to 10.6 nmol/l (SD1.4) in patients with high tHcY(p<0.001). Levels of 
vitamin B12 were also significantly higher in patients with low tHcY, 433 pmol/l 
(SD 55) compared to 380 pmol/l (SD 70) in patients with high tHcY(p<0.05). No 
other differences in baseline characteristics between groups existed.  
Table 1 
Baseline characteristics 
 
Homocysteine level < 15 µmol/l  ≥15 µmol/l P value* 
 
Age (years) 56.2 53.0 0.15 
Male/female 17/2 17/2 1.0 
Smoking (yes) 4 5 0.72 
Hypertension (yes) 4 5 0.72 
Hyperlipidemia 16 16 1.0 
Family history 11 9 0.54 
Statin therapy 16 15 0.98 
Homocysteine (µmol/l) 10.6 (2.2) 17.9 (1.7) <0.0001 
Total Cholesterol (mmol/l) 5.41 (0.4) 5.68 (1.0) 0.30 
LDL-cholesterol (mmol/l) 3.55 (0.4) 3.91 (0.8) 0.11 
HDL-cholesterol (mmol/l) 1.04 (0.18) 1.01 (0.19) 0.65 
Triglycerids (mmol/l) 1.6 (0.2) 1.6 (0.6) 0.94 
Folic acid (nmol/l) 13.9 (1.9) 10.6 (1.6) <0.001 
Vitamin B12 (pmol/l) 433 (55) 380 (70) <0.05 
Creatinine (µmol/l) 97 (6) 92 (9) 0.11 
Glucose (mmol/l) 5.32 (0.4) 5.18 (0.7) 0.55 
 
*p value using one way analysis (ANOVA) or Chi Square test where appropriate 
†between brackets: SD 
 
Response of CBF to acetylcholine (table 2): 
Baseline CBF(ml/min) was 54.7 ml/min (SD 24) in patients with normal plasma 
homocysteine levels compared to 49.2 ml/min (SD 13) in hyperhomocysteinemic 
patients p=0.39; (95% C.I –7.4 ml/min to +18 ml/min). In 21 out of 38 patients 
the increase of coronary blood flow following subsequent dosages of 
acetylcholine was abnormal, 16 patients with elevated plasma homocysteine 
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levels and five patients with a normal tHcY. In subjects with normal tHcY, CBF 
(ml/min) increased at the maximal dosage of AcH from 54.7 ml/min to 114.2 
ml/min (SD 71) compared to an increase from 49.2 ml/min to 51.9 ml/min (SD 
26) in hyperhomocysteinemic patients (p<0.01) (95% C.I. 42-163). Figure 1 
demonstrates the response in CBF (%) to subsequent amounts of AcH and nitro-
glycerine. Response differences  in CBF (%) between the two groups following 
two subsequent amounts of acetylcholine infusion (10-7M and 10-6M) 
demonstrated a mean  increase in CBF of 10% (SD 40) for patients with high 
tHcY compared to a mean increase of 88 % (SD 91) for patients with a normal 
tHcY (p<0.001) (95% C.I. 59-124) (Repeated Measures Model).  
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Figure 1  
Effect of acetylcholine and nitroglycerin on percent change in coronary blood flow in both groups. 
=total plasma homocysteine < 15 µmol/l. , = total plasma homocysteine ≥15 µmol/l. *p< 0,001 
for the response differences  in CBF (%) between the two groups following two subsequent amounts 
of acetylcholine infusion (10-7M and 10-6M) (95% C.I. 59%-124%) (Repeated Measures Model). 
 
 
When corrected for folic acid or vitamin B12 the difference is still significant 
(p<0.05 and p<0.001 respectively). Odds ratio (OR) for the association of 
hyperhomocysteinemia and coronary endothelial dysfunction was  14.9 (95%  
C.I. 3.0-74.0) p<0.01). 
% change CBF 
 Base AcH AcH  AcH NTG 
 10-8M 10-7M  10-6M 
* 
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Spearman rank correlation coefficients for the association of tHcY and maximal 
change in CBF(%) was –0.43 (p<0.005) (Figure 2). When corrected for folate 
and vitamin B12, spearman rank correlation coefficient was –0.30 (p=0.042). 
Endothelium independent vasodilatation following the administration nitro-
glycerine 200 µg was comparable for both groups (p=0.94). 
 
 
 
Figure 2 
Scatter plot depicting the maximal change in coronary blood flow (CBF) (%) following acetylcholine 
(10-6M).Spearman rank correlation coefficient r=-0.43, p<0.005 for the association of plasma 
homocysteine levels and maximal change in coronary blood flow 
 
Response of MSD and MOD to acetylcholine (table 2): 
Mean segment diameter (MSD) at baseline was comparable between the 
groups(p=0.67). Mean MSD decreased from 2.46 mm (SD 0.53) to 2.11 mm (SD 
0.72) following the administration of AcH 10-6 M.  
0
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R = -0.43 
p<0.005 
Plasma homocysteine (µmol/l) 
% change CBF 
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Table 2  
 
Coronary flow and epicardial diameter following infusion of acetylcholine   
 
     
Homocysteine level < 15 µmol/l   ≥15 µmol/l  P value* 
 
       
CBF  (ml/min) % change  (ml/min) % change 
  
Baseline  54.7 (24) †   49.2(13) 
AcH 10-8 M  69.3(35) 26.8%  51.7(18) 5.3%  0.03 
AcH 10-7 M  91.5(54) 67.9% 56.6 (18) 14 %  <0.01 
AcH 10-6 M  114.2(71) 108.7% 51.9(26) 5.4% <0.001 
 
MSD (mm) % change (mm) % change 
baseline  2.52(0.6)  2.39(0.4) 
AcH 10-8 M 2.48(0.6) -2.5% 2.34(0.5) -2.4% 0.57  
AcH 10-7 M  2.40(0.6) -4.8 % 2.18(0.5) -9.1% 0.52 
AcH 10-6 M  2.09(0.8)-17.2 % 2.06(0.5) -14.0 %  0.39 
 
MOD (mm) % change (mm) % change 
Baseline  1.91(0.5)  1.86(0.3)   
AcH 10-8 M   1.85(0.5) -3.2 % 1.73(0.4)  -7.3 %   0.20 
AcH 10-7 M  1.82(0.5) -4.3 % 1.61(0.4) -13.6 %  0.06 
AcH 10-6 M  1.54(0.7) -19.6 % 1.55(0.4) -16.7 %  0.52 
 
*p value one way analysis of variance (ANOVA) (for the difference in mean % change) 
† between brackets: SD 
 
 
Figure 3    Figure 4 
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-■ homocysteine ≥ 15 µmol/l 
-♦ homocysteine < 15 µmol/l 
-■ homocysteine ≥ 15 µmol/l 
-♦ homocysteine < 15 µmol/l 
 Base AcH AcH AcH NTG 
  10-8M 10-7M 10-6M 
 Base AcH AcH AcH NTG 
  10-8M 10-7M 10-6M 
% change MSD % change MOD 
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Figure 3 demonstrates changes in MSD following subsequent dosages of AcH 
and nitro-glycerine for both groups.  Changes in MSD (%) following the 
administration of to subsequent amounts of AcH (10-7M and 10-6M) were 
comparable for both groups (p=0.39). Minimal obstruction diameter (MOD) at 
baseline was comparable between the groups (p=0.67). Mean MOD decreased 
from 1.85 mm (SD 0.41) to 1.53 mm (SD 0.55) following the administration of 
AcH 10-6M. Figure 4 demonstrates changes in MOD following subsequent 
dosages of AcH and nitro-glycerine for both groups. Changes in MOD (%) 
following the administration of subsequent amounts of AcH (10-7M and 10-6M) 
were comparable for both groups (p=0.52). No differences occurred following 
the administration of nitro-glycerine. 
 
Discussion 
This study demonstrated a strong and graded effect of tHcY on coronary 
endothelial function, expressed as change in coronary blood flow.  
 
Acetylcholine induced changes in CBF and cardiovascular prognosis 
Acetylcholine is widely used as standard substance to test endothelial function in 
human coronary arteries [9]. In subjects with normal coronary vessels, 
acetylcholine induces vasodilatation of epicardial coronary vessels and an 
increase of CBF of 50% or more [7]. In patients with atherosclerosis, or in the 
presence of risk factors for vascular disease like hypercholesterolaemia, 
hypertension, diabetes mellitus or smoking, acetylcholine induced paradoxical 
vasoconstriction of epicardial conductance vessels, expressed as a decrease in 
MSD and MOD, and a smaller increment of CBF [9]. Coronary endothelial 
dysfunction, expressed as a change in CBF, is associated with increased 
cardiovascular events [10,11,12].  
In our study, the patients in the group with a normal tHcY showed a mean 
increase of CBF following two subsequent dosages of AcH of 88% while in the 
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group of patients with an abnormal tHcY there was only 10 % increase of CBF 
suggesting that the prognosis of patients with high tHcY is unfavorable 
compared to patients with a normal tHcY and a normal reaction to acetylcholine. 
We also demonstrated a decrease in MSD and MOD suggesting that baseline 
endothelial function in both groups was abnormal. However, in contrast to 
changes in CBF, the relationship between paradoxical vasoconstriction of 
epicardial vessels, represented as change in MSD and MOD, and cardiovascular 
mortality and morbidity is less clear.  
 
Homocysteine and endothelial function 
Endothelial cells synthesize and release vasoactive mediators and thereby 
modulate vascular tone. Nitric oxide (NO) and prostacyclin are the best 
characterized vasodilatators and are largely responsible for endothelium 
dependant vasodilatation in epicardial coronary vessels. However, not all 
endothelium-dependant relaxation can be explained by NO or prostacyclin. Some 
studies have provided compelling evidence for the existence of another factor, 
endothelium-derived hyperpolarizing factor (EDHF) that is especially important 
in resistance vessels [13]. In humans with coronary atherosclerosis, endothelial 
vasodilatator function is not confined only to epicardial conductance vessels but 
extents also to the coronary resistance vessels. Coronary blood flow in the 
absence of obstructive lesions is regulated mainly by the coronary resistance 
vessel [14]. Mechanisms responsible for endothelial dysfunction in 
hyperhomocysteinemia are poorly understood. Several investigators have shown 
that homocysteine reduces the bioavailability of NO and enhances smooth 
muscle cell proliferation, both of which are important markers of 
atherothrombotic disease [2]. Recently it was hypothesized that 
hyperhomocysteinemia may stimulate the formation of asymmetrical 
dimethylarginine, an endogenous inhibitor of NO synthase [15] . The relationship 
between hyperhomocysteinemia and EDHF is unclear. 
Several investigators have focused on the relationship between tHcY and 
endothelial function using the flow-mediated forearm model. Recently, Doshi et 
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al. demonstrated that improvement of flow-mediated vasodilatation occurred 
within four hours after the ingestion of folic acid while homocysteine in plasma 
remained unchanged [16]. They suggested that folic acid improves endothelial 
function in coronary artery disease acutely by a mechanism largely independent 
of homocysteine. This may be in contradiction with the findings by some other 
investigators of a positive correlation between tHcY and flow-mediated 
vasodilatation [17,18,19] although these results are not unequivocal [20,21]. 
Although a study in coronary vessels can be biased due to the selection of 
patients with coronary artery disease (for obvious ethical reasons), our study 
adds important evidence to the hypothesis that hyperhomocysteinemia induces 
coronary endothelial dysfunction.  
 
Coronary blood flow and acetylcholine 
Factors known to impair endothelial function in the coronary circulation 
expressed, as changes in MSD and MOD are also associated with impaired flow 
mediated dilatation in the brachial artery [4,5]. However, the relationship 
between change in CBF and impaired flow mediated dilatation of the brachial 
artery is less clear. In all patients, we found a paradoxical vasoconstriction in the 
epicardial vessels, expressed as a decrease in MSD and MOD, after 
administration of acetylcholine. However, in patients with a normal tHcY level 
there was a normal increase in CBF and in patients with an elevated tHcY a 
blunted CBF increment. Our results suggest that homocysteine has therefore 
primarily an adverse effect on endothelial function in the coronary resistance 
vessels.  
Abnormal coronary blood flow changes during administration of endothelium 
dependant vasodilatators like acetylcholine in patients without obstructive 
coronary artery disease are associated with cardiovascular morbidity and 
mortality [7,22]. Since tHcY is associated with cardiovascular mortality and 
morbidity[23,24] , these changes in CBF may therefore explain, at least partially, 
the role of homocysteine in cardiovascular disease.  
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Influence of folic acid and vitamin B12 
In our study tHcY is inversely related to blood levels of folic acid (r=-0.69, 
p<0.0001) and vitamin B12 (r=-0.55, p<0.001), as has been reported before [25]. 
It is possible that low folate and not elevated tHcY levels are responsible for the 
abnormal reaction to acetylcholine. However, when corrected for folate or 
vitamin B12 there is still a significant association between acetylcholine-induced 
changes in CBF and tHcY suggesting that these changes are at least in part 
homocysteine dependant. 
 
Conclusions 
We concluded that change in coronary blood flow as an expression of coronary 
endothelial function is strongly and gradually related to total plasma 
homocysteine levels in patients with coronary artery disease. 
 
Study limitations: 
This study can be biased due to the relative small number of patients. Also, the 
selection of patients with established coronary artery disease (for ethical reasons) 
may have biased our results. However, since baseline characteristics and baseline 
CBF, MSD and MOD were comparable for both groups the results of this study 
may add evidence to the concept that elevated plasma homocysteine levels are 
related to coronary endothelial function. 
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Introduction 
 
Hyperhomocysteinemia is an important risk factor for premature cardiovascular 
disease.  Until now more than 80 studies have been published upon the 
association between homocysteine and vascular disease [1]. Homocysteine levels 
can be reduced 25% to 30 % using folic acid and supplementation of vitamin 
B12 provides additionally 7% reduction. This reduction is higher in 
hyperhomocysteinemic patients and patients with a low pretreatment folate status 
[2]. The pathophysiological mechanisms responsible for the increased risk 
remain unclear. Generally it is assumed that homocysteine is toxic to the 
vascular wall and causes endothelial dysfunction [3]. Endothelial dysfunction is 
a key mechanism in the current hypothesis of atherothrombosis and it is shown 
that functional impairment of the endothelial function defined as an impairment 
of endothelium-dependent coronary blood flow precedes significant arterial 
vessel disease [4]. Until now it is unknown whether homocysteine-lowering 
therapy will improve prognosis in patients with elevated homocysteine levels and 
coronary artery disease. Some investigators have shown that folic acid improves 
endothelial function in the forearm model in patients with coronary artery 
disease [5]. However until now it is unclear whether homocysteine-lowering 
therapy improves coronary endothelial function. The aim of this study was to 
evaluate the effect 6 months of therapy with folic acid 5mg in combination with 
cobalamin 400 µg on coronary endothelial function in hyperhomocysteinemic 
patients with symptomatic coronary artery disease. 
 
Methods 
Patient selection 
This study is a double blind randomized, placebo controlled study with a follow 
up of 6 months investigating the effect of folic acid 5 mg and cobalamin on 
coronary endothelial function. Cobalamin 400 µg was added to avoid unopposed 
folic acid treatment in undiagnosed vitamin B12 deficiency. Endpoints were 
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ACH-induced changes in endothelium-dependent coronary blood flow at 
baseline and after 6 months of therapy. Other endpoints were change in mean 
segment diameter (MSD), and in minimal obstruction diameter (MOD) of a pre-
defined segment of a coronary vessel, after infusion of ACH. 
Patients with objectively confirmed ischemic heart disease who were referred for 
elective PTCA between April 1997 and June 1999 to our catheterization 
laboratory were eligible for this study. Inclusion criteria were a plasma 
homocysteine level of 15.5 µmol/l or more, age between 18 and 70 years, and at 
least one coronary vessel without a significant stenosis (stenosis < 50%). Patients 
who used medication or vitamins involved in homocysteine metabolism were 
excluded from this study as were patients with diabetes mellitus and patients 
with uncontrolled hypertension. During follow up patients were asked to make 
no changes in their diet or exercise levels. Patients in whom a coronary stent was 
placed received 160 mg of acetylsalicylic acid instead of 80 mg in the first 
month. Otherwise, the medication was kept unchanged when possible. Patients 
with kidney failure reflected as a creatinine level of more than 150 µg /l or 
serious liver failure were also excluded. Patients returned after 2, 8, 12 and 23 
weeks for reassessment of lipid profile, vitamin levels, homocysteine levels and 
clinical signs of recurrent angina pectoris. The ethical committee of our 
institution approved the protocol. Written informed consent was obtained in all 
patients.  
 
Coronary angiography 
Long acting nitrates were withdrawn 24 hours before the procedure and replaced 
by short acting nitrates if necessary. All procedures were performed under the 
same conditions in time and location. After the performance of the elective 
PTCA a new guiding catheter 7 Fr. (Medtronic) was placed in a non-dilated 
coronary artery without a stenosis (≤ 50%). A Doppler guide wire (0.014 inch 
diameter), (Flowire, Endosonics Incorporated) within a 2.2 F coronary infusion 
catheter (Medtronic) was advanced in the vessel of interest just distal to a 
landmark of a proximal epicardial segment, defined as an important side branch 
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of a coronary vessel, with a diameter of at least 2.0 mm. After achieving a stable 
velocity signal, adenosine 18 µg was administered through the guiding catheter 
for maximal hyperemia and endothelium-independent coronary flow velocity 
was measured. Assessment of endothelium-dependent vasodilatation and 
coronary flow was performed by selective infusions of ACH with a total amount 
of 10-8 M, 10-7 M, 10-6M respectively. ACH was dissolved in NaCl 0.9% and 
infused with a Terumo® pump at a rate of 2ml/min during 3 minutes. 
Nitroglycerin 200 µg was then injected as a bolus. 
Before infusion of ACH baseline angiography was performed using Hexabrix® 
with biplane technique. Then ACH infusion started. After each infusion of ACH 
a coronary angiography followed. This procedure was performed at base line and 
after 6 months of treatment. 
 
Assessment of coronary blood flow 
Doppler flow velocity spectra were analyzed to determine time-averaged peak 
velocity. Volumetric coronary blood flow (CBF) is the cross sectional area times 
average peak velocity times 0.5[6]. The cross sectional area is the mean area 
over a distance of 5 mm in the segment 5 mm to 10 mm distal to the tip of the 
Flowire. Endothelium-dependent coronary flow reserve is calculated as percent 
change in CBF in response to ACH. Normal coronary endothelium-dependent 
function is defined as an increase of CBF of 50% or more [7]. The endothelium-
independent coronary flow velocity reserve (CVR) was calculated by dividing 
the average peak velocity by the baseline average peak velocity after 18 µg 
adenosine injection.  
 
Quantitative coronary angiography 
Analysis of baseline and follow-up angiographies was performed using the 
CAAS II QCA software (Pie Medical, Maastricht, The Netherlands). Analysis of 
MOD and MSD started at an important side branch of the epicardial vessel and 
continued until the second important side branch of the segment. Care was taken 
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to ensure that the same segment of the coronary vessel was examined at baseline 
and follow-up. Therefore the films were examined in the same session to ensure 
analysis of the identical portion of the vessel. The investigators were blinded for 
the treatment regimen during analysis of the coronary angiography. 
 
 
Laboratory measurements 
After an overnight fasting a sample of venous blood was drawn on EDTA tube 
from the patients and put on ice immediately. Samples were stored at -20ºC and 
analyzed within one week. Plasma total homocysteine was measured by high 
performance liquid chromatography. After 6 months a second homocysteine 
sample was taken to investigate the effects of folic acid and cobalamin on 
homocysteine levels. Also samples for vitamin analysis and lipids were analyzed 
at baseline and follow up. 
 
Statistics 
Data are expressed as mean ± standard deviation (SD). Analysis of baseline data 
was performed using Chi-Square test or Mann-Whitney test where appropriate. 
Response differences in CBF, MSD and MOD, following two subsequent 
amounts of acetylcholine infusion (10-7M and 10-6M) were compared in two 
conditions (before treatment and after treatment) using a double multivariate 
repeated measures model (General Linear Model, SPSS 10.1). 
 
Results 
 
In the period of 2 years, eighteen patients were recruited in the study, three 
patients were excluded during follow up because of symptomatic re-stenosis in 
the PTCA vessel, two in the folic acid group, one in the placebo group. Thus, 
follow-up coronary angiography could be obtained in 15 patients, seven in the 
folic acid group and eight in the placebo group. Two women and 13 men 
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completed the study. Mean age was 52.2 years (range 40-66 years). Of the study 
group baseline homocysteine levels were 17.9 µmol/l (range 15.6-21.2). Other 
baseline characteristics of the treatment and placebo group are listed in table 1.  
 
Table 1 
 
Baseline characteristics 
  
 Folic acid/cobalamin placebo group  p value 
 group (n=7)  (n=8)  
 
Age (mean) (yrs) 53.4 (range 40-63) 51.3 (range 42-66) 0.54 
Male/female patients  7/0  7/1  0.73 
Smoking  2  1  0.44 
Hypertension  1  2  0.61 
Hyperlipidemia  6  6  0.61 
Family history  5  2  0.07 
Beta blockers  6  8  0.27 
Calc.antagonist  4  3  0.45 
Nitrates    3  3  0.83 
Acetylsalicylic  7  8  1.0 
ACE inhibitors  1  2  0.61 
Statins    4  5  0.19 
Homocysteine,µmol/l 17.1 (0.9)*  18.7 (2.0)* 0.15 
Total cholesterol, mmol/l 6.07 (1.3)  5.56 (0.9) 0.40 
HDL-cholesterol, mmol/l 1.06 (0.11)  0.93 (0.19) 0.23 
LDL-cholesterol, mmol/l 4.29 (1.1)  3.96 (0.5) 0.61 
Triglycerides, mmol/l 1.7 (0.8)  1.7 (0.5)  1.0 
Folic acid, nmol/l  11.2 (1.3)  10.3 (1.4) 0.09 
Vitamin B12, pmol/l 415( 95)  345 (38)  0.12 
Glucose (fasting), mmol/l 5.08 (0.7)  5.40 (1.0) 0.69 
Kreatinine, µmol/l 93 (10)  92 (13)   0.54 
 
*Between brackets: SD. 
 
 
In the folic acid/cobalamin group in 4 patients the right coronary artery (RCA) 
was used for analysis, in 2 patients the ramus circumflexus (RCX) and in 1 
patient the left anterior descending artery (LAD). In the placebo group in 4 
patients the RCA was used for analysis, in 3 patients the RCX and in 1 patient 
the LAD. No significant differences between groups were found. In the folic 
acid/cobalamin group total plasma homocysteine decreased 31.5 % from 
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17.1µmol/l (SD 0.91) to 11.7 µmol/l (SD 1.59) (p<0.0001) as compared to no 
change in the placebo treated group. In the folic acid/cobalamin group plasma 
folic acid improved from 11.2 nmol/l (SD 1.3) to 26.9 nmol/l (SD 3.4) 
(p<0.0001) and plasma vitamin B12 improved from 415 pmol/l (SD 95) to 463 
pmol/l (SD119) No changes occurred in the placebo treated group. All other 
biochemical parameters remained unchanged (table 2).  
 
Table 2  
 
Changes in risk factors 
 
 Folic acid  p value* placebo group p value * 
  
 cobalamin  
 group (n=7)  (n=8) 
 
Homocysteine, µmol/l   
 Baseline 17.1 (0.91)† <0.0001 18.7 (1.97) 0.92  
 Follow-up 11.7 (1.59) 18.8 (2.21) 
Serum folate, nmol/l 
 Baseline 11.2 (1.3) <0.0001 10.3 (1.4) 0.90 
Follow-up 26.9 (3.4) 10.4 (1.3)   
Vitamin B12, pmol/l 
 Baseline 415 (95) 0.42 346 (38) 0.98 
 Follow-up 463 (119) 348 (41) 
Total cholesterol, mmol/l 
 Baseline 6.07 (1.3) 0.63 5.66 (0.9) 0.97 
 Follow-up 5.77 (0.9) 5.55 (0.6)   
HDL cholesterol, mmol/l 
 Baseline 1.06 (0.12) 0.87 0.93 (0.19) 0.68 
 Follow-up 1.04 (0.13) 0.99 (0.19) 
LDL cholesterol, mmol/l 
 Baseline 4.24 (1.15) 0.62 3.87 (0.69) 0.98 
 Follow-up 3.97 (0.81) 3.85 (0.46) 
Triglycerides, mmol/l 
 Baseline 1.69 (0.85) 0.94 1.67 (0.34) 0.60 
 Follow-up 1.66 (0.72) 1.54 (0.38) 
Mean arterial pressure , mm Hg 
 Baseline 105 (16) 0.92 111 (14) 0.68 
 Follow-up 107  (9) 108 (8) 
 
* p value for difference between baseline and follow up with Mann-Whitney test. 
† between brackets: SD 
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In all patients with complete follow up, medication during follow up was not 
changed. No significant differences in changes in CBF, MSD and MOD were 
seen at baseline (table 3).  
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Figure 1 
Effect of acetylcholine and nitroglycerin on percent change in volumetric coronary 
blood flow in both groups. 
=Baseline, = follow-up. * p=0.15 for the difference between baseline and follow up at maximal 
dosage of acetylcholine (placebo group). ** p< 0,05 for the difference between baseline and follow 
up at the maximal dosage of acetylcholine (folic acid/cobalamin group). 
P<0,005 for the difference at baseline and follow up between the placebo group and the folic 
acid/cobalamin group with General Linear Model 
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Figure 2 
Effect of acetylcholine and nitroglycerin on percent change in mean segment diameter in both 
groups. 
=Baseline, = follow-up.* p=0.09 for the difference between baseline and follow up at maximal 
dosage of acetylcholine (placebo group). **p= 0.10 for the difference between baseline and follow up 
at the maximal dosage of acetylcholine (folic acid/cobalamin group). 
P=0.15 for the difference at baseline and follow up between the placebo group and the folic 
acid/cobalamin group with General Linear Model 
* 
** 
** 
* 
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Figure 3: 
Effect of acetylcholine and nitroglycerin on percent change in minimal obstruction diameter in both 
groups.=Baseline, = follow-up. * p = 0.06 for the difference between baseline and follow up at 
maximal dosage of acetylcholine (placebo group). ** p =0.26 for the difference between baseline and 
follow up at the maximal dosage of acetylcholine (folic acid/cobalamin group). 
 
Table 3 
 
 Baseline coronary flow parameters following infusion of acetylcholine 
 
 Folic acid/ placebo group p value 
cobalamin group 
 n=7  n=8 
 
Mean Change in  10-8M 38.6 (29)* 10.8(15)  0.051 
Volumetric coronary 10-7M 39.2 (46)  33.1 (42)  0.79 
 blood flow (%)  10-6M 15.6 (36)  16.3 (35)  0.96 
   NTG 204.3 (133) 228.7 (137) 0.73 
  
Mean Change in   10-8M -3.5 (1.7)  -1.7 (4.5)  0.64 
Mean segment diameter 10-7M -7.6 (3.8)  -11.0(7.9) 0.06 
(%)   10-6M -13.9(6.2) -12.1(8.9) 0.08 
   NTG 6.1 (7.2)  8.0 (9.7)  0.39 
 
Mean Change in   10-8M -6.7 (7.4)  -8.6 (9.8)  0.40 
Minimal obstruction 10-7M -13.4 (6.5) -13.6(10.6) 0.28 
diameter (%)  10-6M -16.2 (9.4) -18.9 (18.3) 0.37 
   NTG 7.0 (5.2)  4.9 (6.0)  0.02 
 
*SD between brackets 
 
* ** 
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Changes in CBF, MSD and MOD are calculated following the administration of 
the highest dosage of ACH. Changes in CBF, MSD and MOD after infusion of 
ACH at baseline were abnormal in all patients. At follow-up, after infusion of 
ACH, CBF increased in the folic acid/cobalamin group from 39.5 ml/min (SD15) 
to 77.5 ml/min (SD33) (p<0.01). In the placebo treated group volumetric 
coronary blood flow decreased from 53.2 ml/min (SD18) to 40 ml/min (SD16) 
(p=0.38). CBF in the folic acid/cobalamin treated group improved 96% (SD 58), 
(95% C.I.: 44%-154%) (p<0.05) as compared to a decrease of 16 %(SD 35), 
(95% C.I.:  –20%- +30%) (p=0.15) in the placebo treated group. P<0.005 for the 
change in CBF at baseline and follow-up between the folic acid/cobalamin group 
and the placebo group with the General Linear Model (Figure 1). Mean segment 
diameter (MSD) decreased from 2.19 mm (SD0.22) to 1.83 mm (SD 0.14) in the 
placebo treated group and increased from 1.99 mm (SD 0.15) to 2.12 mm (SD 
0.14) in the folic acid/cobalamin group. MSD decreased 16.4% in the placebo 
treated group and increased 6.5 % in the folic acid/cobalamin group (p=0.15) 
(figure 2). Minimal obstruction diameter  (MOD) decreased from 1.76 mm 
(SD0.13) to 1.43mm (SD 0.09) in the placebo group and increased from 1.41 
mm (SD 0.16) to 1.60 mm (SD 0.14) in the folic acid/cobalamin group. MOD 
increased 13.4 % in the folic acid/cobalamin group and decreased 18.7% in the 
placebo treated group (p=0.14) (figure 3). Endothelium-independent 
vasodilatation as presented in CVR was 2.78 (SD 0,29) at baseline in the placebo 
group and 2.91 (SD 0.32) in the folic acid/cobalamin group. In both groups CVR 
did not change significantly at follow up. 
  
Discussion 
 
This is the first study on changes in endothelium-dependent coronary flow in 
hyperhomocysteinemic patients with symptomatic coronary artery disease 6 
months after treatment with folic acid and cobalamin. This regime significantly 
improved volumetric coronary blood flow, MSD and MOD. Since clinical trials 
Homocysteine-lowering therapy  and improvement of endothelial function 
 120 
evaluating the effect of homocysteine-lowering therapy on clinical endpoints in 
patients with mild hyperhomocysteinemia are not yet available, our research 
focused on endothelial dysfunction as key mechanism in homocysteine–induced 
vascular disease.  
 
Homocysteine and endothelial function 
So far, angiographic studies on the association between plasma homocysteine 
levels and coronary endothelial function have not been published but some 
human studies used the reactive hyperemia model of the brachial artery 
demonstrating that severe hyperhomocysteinemia is associated with reduced 
flow-mediated vasodilatation [8]. Also in patients with mild 
hyperhomocysteinemia the plasma homocysteine level was a significant 
predictor of reduced flow-mediated vasodilatation [9,10]. In the forearm model, 
folic acid prevented the impairment endothelium-dependent vasodilatation after 
methionine loading [11] and ameliorated endothelium-dependent vasodilatation 
in patients with familial hypercholesterolaemia and normal tHcy [12,13]. 
However, the effect of folic acid on endothelial function correlated with tHcy 
suggesting that folic acid is more effective in patients with high tHcy [14]. 
 
Endothelial function in epicardial vessels and resistance vessels. 
ACH is widely used as standard substance to test endothelial function in human 
coronary arteries [15]. In subjects with normal coronary vessels, ACH induces 
vasodilatation of coronary vessels. In patients with atherosclerosis, or in the 
presence of risk factors for vascular disease like hypercholesterolaemia, 
hypertension, diabetes mellitus and smoking, ACH has been shown to induce 
paradoxical vasoconstriction [16]. All patients in the study group had severe 
coronary endothelial dysfunction following infusion of ACH at baseline. 
Changes in MSD after intracoronary infusion of ACH show a coronary 
endothelial dysfunction expressed as a decrease in MSD at baseline. The same is 
true for changes in MOD. Volumetric coronary blood flow in all patients was 
severely disturbed at baseline. Follow-up demonstrated a significant 
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improvement of volumetric coronary blood flow in the patients who used folic 
acid and cobalamin. The changes in MSD improved after infusion of ACH at 
follow-up in the folic acid/cobalamin group as compared to the placebo group. 
Changes in MOD improved also albeit not significantly.  
Our patients were characterized by an abnormal response upon ACH infusion at 
baseline. Since improvement of ACH-induced vasoconstriction depends on the 
response at baseline we could expect a stronger improvement of endothelial 
response on ACH infusion after intervention [17].  
Suwaidi et al. demonstrated that severe coronary endothelial dysfunction, 
defined as an increase of volumetric coronary blood flow less then 20% after 
infusion of ACH, in the absence of significant coronary artery disease, is 
associated with an increase in cardiac events in the follow up [4]. This supports 
the concept that coronary endothelial dysfunction is an important marker for 
future progression of coronary vascular disease. Assessment of CVR, 
demonstrated that, in our study, all patients at baseline and follow-up had a CVR 
within the normal range of 2.7 +/-0.6 testifying that the investigated coronary 
vessels at baseline and follow-up had no significant stenosis which could 
influence changes in volumetric coronary blood flow, changes in MSD and 
MOD [18]. Our results supports, that hyperhomocysteinemic patients, by using 
folic acid and cobalamin might improve their cardiovascular prognosis. 
 
 Mechanisms of endothelial dysfunction . 
 Many observational, case-control and prospective studies have been published 
upon the association of hyperhomocysteinemia and coronary artery disease [1]. 
However, these studies cannot exclude the possibility that 
hyperhomocysteinemia is rather a marker of vascular disease than being causally 
related to vascular disease. Mechanisms responsible for endothelial dysfunction 
in hyperhomocysteinemia are poorly understood. Several investigators have 
shown that homocysteine reduces the bioavailability of nitric oxide and enhances 
smooth muscle cell proliferation, both of which are important markers of 
atherothrombotic disease [3]. Recently it was hypothesized that 
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hyperhomocysteinemia may stimulate the formation of asymmetrical 
dimethylarginine, an endogenous inhibitor of nitric oxide synthase [19].  
 
 Folic acid and restoration of endothelial function. 
Folic acid reduces homocysteine levels 25% and addition of cobalamin led to a 
further reduction of 7%[2,20]. In our study plasma homocysteine levels reduced 
31 % after 6 months of treatment with folic acid 5 mg and cobalamin 400 µg 
compared to no change in the placebo treated group. The mechanism responsible 
for the effect of folic acid is unclear. Apart from lowering of homocysteine, folic 
acid may influence endothelial function via other mechanisms. Folates are also 
involved in endogenous restoration of tetrahydrobiopterin, an essential cofactor 
for nitric oxide synthase [21].  Tetrahydrobiopterin restores endothelial function 
in the forearm model in hypercholesterolemic patients [22]. Other studies 
suggest an anti-oxidant effect of folic acid [12]. Improvement of endothelial 
function by anti-oxidant supplementation has been studied before but, until now 
the results are variable and more extensive studies are needed to resolve the 
question whether anti-oxidant therapy is useful in patients with coronary artery 
disease [14,23]. 
Also the natural outcome of untreated homocystinuria patients, with fasting 
plasma homocysteine levels > 100 µmol/l and a 50% risk of suffering from a 
vascular event before the age of 30 years suggests a strong effect of 
homocysteine on vascular disease [24]. In these patients with severe 
hyperhomocysteinemia appropriate homocysteine-lowering therapy reduced the 
risk on vascular events significantly with more then 90%[25]. Our study adds 
evidence to the concept that homocysteine-lowering therapy is clinical beneficial 
in patients with elevated homocysteine levels.  
 
Study limitations. 
Despite the relative small number of patients significant differences in coronary 
endothelial function after intervention were observed in the same range as seen 
in studies with cholesterol-lowering therapy. However, although this study may 
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add evidence to the fact that treatment of hyperhomocysteinemia may be useful 
in vascular disease ongoing intervention trials with clinical endpoints are needed 
to answer the question whether treatment of hyperhomocysteinemia indeed 
reduces cardiovascular events. 
 
Conclusions. 
We conclude that volumetric coronary blood flow as an expression of coronary 
endothelial function improves significantly after 6 months of treatment with folic 
acid and cobalamin in hyperhomocysteinemic patients with symptomatic 
coronary artery disease. 
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Introduction  
 
Evidence is accumulating that a disturbed homocysteine metabolism provokes 
endothelial dysfunction. Vascular endothelial dysfunction is an early sign of 
atherosclerotic disease and it is more and more used as a surrogate end point for 
an increased cardiovascular risk. Several studies have demonstrated a prompt 
beneficial effect of folates in vascular disease using the fore-arm model showing 
an improvement of endothelial function[1]. However, the relevance of the fore-
arm model in cardiovascular prognosis is unequivocal. The results of these 
studies should therefore be judged critically when they are used as a surrogate 
endpoint for vascular events. On the contrary, studies evaluating coronary 
endothelial function can , when assessed with quantitative coronary angiography 
and doppler velocity measurements, predict cardiovascular prognosis [2,3]. In a 
recent study, we demonstrated a beneficial effect of long-term folate therapy in 
hyperhomocysteinemic patients with coronary endothelial dysfunction at 
baseline[4]. It is unclear whether folates can also improve coronary endothelial 
function immediately. We investigated whether 5-methyltetrahydrofolate (5-
MTHF), the metabolic active form of folate, could instantly improve coronary 
endothelial function in patients with coronary artery disease in a randomised, 
placebo controlled study. 
 
Methods  
 
We investigated the effect of 5-MTHF 1 mg i.v. or placebo on coronary 
endothelial function. Based our previous studie [4], a sample size of 7 would 
have 80% power to detect a significant difference (p<0.05). Twenty patients, 
scheduled for elective PTCA, were randomized for this study.  Coronary 
endothelial function, expressed as a change in coronary blood flow (CBF), was 
evaluated in a non-stenotic coronary vessel using acetylcholine (ACH) infusion 
in dosages of 10-8 M, 10-7M and 10-6 M. CBF is determined using intracoronary 
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doppler velocity and quantitative coronary angiography. Endpoints were ACH-
induced changes in CBF before, and 15 minutes after, the administration of 1 mg 
of 5- MTHF i.v. or placebo (NaCl 0.9%).  Normal coronary endothelium-
dependent function is defined as an increase of CBF of 50% or more [2]. Patients 
using medication or vitamins interfering with homocysteine metabolism were 
excluded from this study. Response differences (%) to the two highest amounts 
of AcH infusion (10-7M and 10-6 M) were compared to the two conditions 
(baseline and follow-up) by using a double multivariate repeated measures model 
(General Linear Model, SPSS 10.1). 
 
Results 
 
20 patients were included, 15 men, 5 women. Baseline characteristics, such as 
risk factors, age and the use of medication, differed not among groups. Mean 
total plasma homocysteine level was 8.7 µmol/l, (SD 2.3). At baseline, following 
the administration of the maximal dosage of ACH, CBF increased from 58 
ml/min, (SD 27) to 113 ml/min, (SD 87) in the 5-MTHF group compared to an 
increase from 48 ml/min (SD 21) to 101 ml/min, (SD 47) in the placebo group. 
15 minutes after the administration of 5-MTHF or placebo, CBF increased from 
58 ml/min, (SD 25) to 91 ml/min, (SD 64) in the 5-MTHF group compared to an 
increase from 42 ml/min, (SD 21) to  99 ml/min, (SD 48) in the placebo group. 
The mean increase of two subsequent amounts of acetylcholine compared to 
baseline was 107% (SD 90) in the 5-MTHF group and 116% (SD 80) in the 
placebo group (p=0.67) (GLM model of repeated measures). (figure 1) 
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Figure 1:  
 
Effect of acetylcholine on change in volumetric coronary blood flow at baseline and follow-up. 
=placebo group, = MTHF group. P=0.94 for the difference at baseline between placebo group 
and MTHF group at the maximal dosage of acetylcholine. P=0.19 for the difference at follow up 
between placebo group and MTHF group at the maximal dosage of acetylcholine. 
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Discussion 
  
This study could not demonstrate a prompt and significant effect of 5-MTHF on 
coronary endothelial function. Our results contrast with most other studies that 
are using endothelial function as a surrogate for cardiovascular events.[1,5]  In 
our study, all patients had a normal increment of CBF suggesting that baseline 
coronary endothelial function was not severely disturbed. It has been 
demonstrated before that in patients with a normal endothelial function folates 
had no effect on endothelial function [5]. The exact mechanism for a possible 
beneficial effect of folates on endothelium is unclear. Some authors suggest that 
folates may have a beneficial effect on endothelial function independently of 
plasma homocysteine levels because homocysteine levels did not change during 
the study [1,5]. However, plasma homocysteine levels may only be a marker of a 
disturbed intracellular homocysteine metabolism.  Intracellular 5-MTHF may 
restore this disturbed homocysteine metabolism because 5-MTHF is a co-
substrate for homocysteine remethylation.  
 
Conclusion 
The administration of 5-MTHF i.v. did not instantly improve coronary 
endothelial function in patients with coronary artery disease. Considering the 
differences in the reported results between the studies evaluating endothelial 
function by using the fore-arm model and our study, we think that studies 
investigating the direct effects of folates on cardiovascular endpoints are now 
essential. 
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Chapter 1 is a general introduction of this thesis outlining the aim of our studies.  
In chapter 2 we review epidemiological evidence of the relationship between 
homocysteine and cardiovascular disease. Chapter 3 presents an introduction to 
homocysteine metabolism in relation to the genetics of hyperhomocysteinemia. 
Chapter 4 focuses on the impact of homocysteine for atherosclerosis and 
endothelial function.  
In chapter 5 we describe the results of a study evaluating the pharmacokinetic 
properties of orally administered 6[R,S] 5-MTHF, the biological active 
diastereoisomer of folates, versus folic acid in subjects with homozygosity for 
the methylenetetrahydrofolate reductase (MTHFR) mutation 677 C→T, 
compared to patients with the wild type genotype. Our results demonstrate that 
5-MTHF has a different pharmacokinetic profile with a better bioavailabity 
compared to folic acid, irrespective of the patients’ genotype. 
In chapter 6 the MTHFR 677C→T mutation is investigated as a genetic risk 
factor of coronary artery disease. The prevalence of the mutation is analysed in 
patients with documented coronary artery disease who participated in the 
Regression Growth Evaluation Statin Study (REGRESS) compared to a control 
population. The results demonstrate that in patients with homozygosity for this 
mutation the prevalence for coronary artery disease was higher compared to 
controls (9.5% compared to 8.5% respectively, odds ratio 1.21 (95% CI: 0.87-
1.68). The results are however not statistically significant. In the meta-analysis 
that is performed on 2476 patients and 2481 controls, the summary estimate of 
the relative risk of the homozygous mutation yields an odds ratio of 1.22 (95% 
CI: 1.01-1.47) indicating that the patients homozygous for this mutation have a 
modest but significant 22% higher risk to develop coronary artery disease. 
Chapter 7 describes the results of a study evaluating the long-term effects of a 
range of doses of folic acid with and without fixed dosages of vitamin B12 and 
vitamin B6. In 130 patients with established coronary artery disease, 200 µg folic 
acid given over a twelve-week period, achieved the same reduction in plasma 
homocysteine concentration as 1 mg folic acid, i.e. 26.1% (95% CI: 21.1-30.8) 
and 19.5% (95% CI 13.0-25.) respectively. The use of vitamin B12 achieved an 
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additional modest reduction of total plasma homocysteine at twelve weeks while 
vitamin B6 achieved no effect. Increased baseline total plasma homocysteine 
levels are associated with a more rapid decline in total plasma homocysteine 
levels after twelve weeks of therapy.  
In chapter 8 we report on the results of a study investigating the effect of 
homocysteine on the extent and progression of coronary atherosclerosis. In 606 
patients participating in the Regression Growth Evaluation Study, a prospective 
randomized double blind placebo-controlled study evaluating the effect of 
pravastatin, fasting total plasma homocysteine levels are determined. 
Quantitative coronary angiography is used at baseline and after two years to 
evaluate the extent and progression of atherosclerosis. Endpoints are change in 
mean segment diameter (MSD) and change in minimal obstruction diameter 
(MOD). This study demonstrates that the number of vessels involved in the 
atherosclerotic process is not related to total plasma homocysteine levels 
(p=0.24). Total plasma homocysteine levels are not related to the number of 
events during follow-up (p=0.97). Follow-up analysis of angiographic data was 
possible in 438 patients. Changes in MSD (p=0.18) and MOD (p=0.68) are not 
associated with total plasma homocysteine levels.  
In chapter 9 we demonstrate the relationship between elevated total plasma 
homocysteine levels and coronary endothelial function, expressed as a change in 
coronary blood flow following infusion of acetylcholine in subsequent doses, in 
patients with coronary artery disease. A plasma homocysteine level of 15 µmol/l 
or more was considered abnormal. Coronary blood flow was determined using 
intracoronary doppler velocity and quantitative coronary angiography. As for 
hyperhomocysteinemic patients, the increase of CBF following two subsequent 
dosages of acetylcholine was abnormal (mean increment 1%) compared to a 
normal increment of coronary blood flow in the patients with normal 
homocysteine levels (mean increment 93%) (p<0.001). The results were 
independent of plasma folate and vitamin B12 levels. 
In chapter 10 we report on the effect of six months of therapy with folic acid 
plus cobalamin on coronary endothelial function, expressed as a change in 
   Chapter 12 
 135 
coronary blood flow, in hyperhomocysteinemic patients with coronary artery 
disease. Fifteen patients scheduled for elective PTCA with plasma 
homocysteine levels of ≥16 µmol/l are randomized after the procedure for six 
months of treatment with folic acid 5 mg and cobalamin 400 µg daily or 
placebo. Coronary blood flow is determined using intracoronary doppler 
velocity and quantitative coronary angiography at baseline and after 6 months of 
treatment. In the folic acid/cobalamin treated group, coronary blood flow 
increased with 96% (SD 54), (95% C.I. 44%-154%) compared to a decrease of 
16% (SD 35), (95% C.I.:  –20%- +30%) in the placebo treated group (p<0.005).  
Chapter 11: In this chapter we describe the results of a randomized, placebo 
controlled study investigating whether 5-methyltetrahydrofolate (5-MTHF), the 
metabolic active form of folic acid, can instantly improve coronary endothelial 
function in patients with coronary artery disease and normal plasma 
homocysteine levels. 
Coronary blood flow is determined using intracoronary doppler velocity and 
quantitative coronary angiography. Endpoints are acetylcholine-induced changes 
in coronary blood flow before, and 15 minutes after, the administration of 1 mg 
of 5- MTHF i.v. or placebo (NaCl 0.9%).  In the 5-MTHF treated group coronary 
blood flow increased 117% compared to an increase of 92% in the placebo group 
(p=0.32) demonstrating no significant effect of 5-MTHF on coronary blood flow. 
 
Discussion 
The hypothesis of a possible relation between hyperhomocysteinemia and 
atherosclerotic disease originated in 1969 when McCully described the presence 
of widespread vascular lesions in a child who died at an age of 7 weeks with 
homocystinuria [1]. Until now however, the question remains whether 
homocysteine is a causal factor in the development of premature atherosclerotic 
disease or just a marker of disease. With regard to the consistency of the 
findings of a positive association between hyperhomocysteinemia and 
premature vascular disease it is important to note that until recently, more than 
20 prospective studies on this topic have been published. Among these, the 
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population-based, nested, case-control studies showed that a 5 µmol/L 
increment in total plasma homocysteine results in a 20–30% increase in 
cardiovascular risk, which is substantially lower than the 60–90% risk 
enhancement shown in the retrospective case-control studies[2]. Recently, the 
meta-analysis of  the Homocysteine Studies Collaboration group demonstrated 
that after adjustment for known cardiovascular risk factors and regression 
dilution bias in the prospective studies, a 25% lower homocysteine level was 
associated with an 11% (OR, 0.89; 95% CI: 0.83-0.96) lower risk on coronary 
artery disease and 19% (OR, 0.81; 95% CI: 0.69-0.95) lower risk on stroke [3].  
The mechanisms responsible for hyperhomocysteinemia as a causal risk factor 
of cardiovascular disease are unclear. Data upon a possible relationship between 
homocysteine and the extent of atherosclerotic lesions in coronary artery disease 
are not unequivocal. Some investigators found a graded effect of homocysteine 
levels on coronary artery disease [4,5,6] while other investigators found no 
relationship[7]. This may be explained by the fact that the investigators used 
different methods to assess the extent of coronary artery disease; none of them 
based on quantitative coronary angiography. It is well known that visual 
estimation of the degree of coronary stenosis is subject to significant operator 
variability[8]. We found no relationship between total plasma homocysteine 
levels and the extent and progression of atherosclerosis using quantitative 
coronary angiography (chapter 8).  On the other hand, evidence is accumulating 
that elevated homocysteine causes endothelial dysfunction. It has been shown 
that homocysteine may reduce the bioavailability of NO and enhances smooth 
muscle cell proliferation, both of which are important markers of 
atherothrombotic disease [9]. Recently, it was hypothesized that 
hyperhomocysteinemia may stimulate the formation of asymmetrical 
dimethylarginine, an endogenous inhibitor of NO synthase [10] . Nitric oxide 
(NO) and prostacyclin are the best characterized vasodilatators and are largely 
responsible for endothelium dependant vasodilatation in epicardial coronary 
vessels. However, not all endothelium-dependant relaxation can be explained by 
nitric oxide or prostacyclin. Some studies have provided compelling evidence 
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for the existence of another factor, the endothelium-derived hyperpolarizing 
factor (EDHF) which is especially important in resistance vessels [11]. As for 
humans with coronary atherosclerosis, endothelial vasodilatator function is not 
confined only to epicardial conductance vessels but extends also to the coronary 
resistance vessels. Coronary blood flow in the absence of obstructive lesions is 
regulated mainly by the coronary resistance vessel [12]. The results of our study 
(chapter 9), using non-stenotic coronary vessels, suggests that EDHF may be 
involved in endothelial dysfunction in hyperhomocysteinemic patients. 
 
Most but not all human studies show a relationship between increased total 
plasma homocysteine levels and impaired endothelial function using a fore arm 
model [9]. Several investigators have demonstrated a beneficial effect of folic 
acid on endothelial function using the forearm model [13,14,15]. In some of 
these studies the results were independent from the patients’ plasma 
homocysteine level [16,17]. But Title et al. demonstrated that the effect of folic 
acid on endothelial function correlated with plasma homocysteine suggesting 
that folic acid is more effective in patients with high homocysteine levels[18]. 
However, the relationship between endothelial dysfunction using the forearm 
model and cardiovascular prognosis is unclear. In contrast, coronary endothelial 
dysfunction, demonstrated by an abnormal change in coronary blood flow 
following the administration of acetylcholine, is an important surrogate 
endpoint in the progression of vascular disease and is associated with increased 
cardiovascular events[19,20,21].  In our study (chapter 9) we could demonstrate 
that changes in coronary blood flow are strongly and gradually related to total 
plasma homocysteine levels in patients with coronary artery disease. In the 
intervention study (chapter 10) we demonstrated a beneficial effect of long term 
treatment with folic acid and cobalamin on coronary endothelial function in 
hyperhomocysteinemic patients. As for patients with normal homocysteine 
levels, we could not find an instantl improvement of coronary endothelial 
function using 5-methyltetrahydrofolate (5-MTHF) compared to placebo 
(chapter 11). The question remains whether folic acid or 5-MTHF can 
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immediately restore coronary endothelial dysfunction or that therapy must be 
continued for a longer period. 
 
Mildly elevated homocysteine levels are caused by genetic as well as 
environmental factors. Several lifestyle determinants like folate intake, smoking 
and coffee intake modulate homocysteine levels causing elevation of plasma 
homocysteine levels[22]. It is therefore inaccurate to assume that the increased 
risk for premature vascular disease associated with hyperhomocysteinemia can 
always be attributed to a single genetic mutation.  
Several investigators have confirmed lowering of elevated homocysteine levels 
using pharmacological amounts of folic acid[23]. The effect of lower, more 
physiological amounts of folic acid on plasma homocysteine levels has been 
investigated demonstrating that even at a dose of 400 µg folic acid, 
homocysteine could be lowered effectively in most patients[24]. In our dose-
finding study (chapter 7) there was no difference in homocysteine-lowering 
effect between 200 µg folic acid and 1 mg folic acid in a twelve-week period. 
These findings suggest that low-dose folic acid treatment in 
hyperhomocysteinemia is sufficient. In 1998 manufacturers in the United States 
fortified flour with folic acid 140 µg/100 g. Jacques et al. determined the effect 
of this intervention in the Framingham Offspring Cohort demonstrating a decline 
of plasma homocysteine of 10 to 50% depending on baseline plasma 
homocysteine levels[25]. However, as has been described in chapter 2, especially 
for patients with severe hyperhomocysteinemia, therapy should be tailored in 
these patients to achieve optimal homocysteine-lowering effect. Secondly, 
considering the patients with the 677 C→T mutation in the MTHFR enzyme the 
results of homocysteine lowering therapy are less unequivocal than described 
above. In a study of Nelen et al. a daily dose of 500 µg was effective even in 
homozygotes for the mutation[26]. Guttormsen et al. however found that the 
response to 200 µg/day was effective in some subjects but not all [27]. Thirdly, 
as in our study (chapter 10) all intervention studies, demonstrating a beneficial 
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effect of folic acid on endothelial function, used folic acid in higher 
dosages[13,14,15,16,17,18, 28, 29].  
 
About 10% of the North-West European populations are homozygous for the 
677 C→T mutation of the MTHFR enzyme. In their meta-analysis, Brattström et 
al[30] found that the total plasma homocysteine concentration was 2.6-µmol/L 
higher in those with the MTHFR 677 TT genotype than in those with MTHFR 
677 CC genotype. With use of data from prospective studies, a 5 µmol/L total 
plasma homocysteine increment can be shown to be associated with an odds 
ratio (OR) of 1.20–1.30. Translated for a difference of 2.6 µmol/L, these odds 
ratios can be estimated as 1.10 to 1.15, respectively. Standard sample size 
calculations show that to detect a relative risk in the range of 1.10–1.15 with a 
power of 80% and a significance level of 5%, 7800–16300 cases and an equal 
number of controls are required. Thus, the insignificant relation between the 
C677T MTHFR polymorphism and cardiovascular disease in our study, 
concerning 735 patients and 1250 controls (chapter 6) does not contradict the 
homocysteine theory. The relative risk of 1.12 associated with the TT genotype 
that was reported by Brattström et al. and our report of a relative risk of 1.21 
(chapter 6) agrees well with the relative risk reported by Klerk et al. in 11.162 
patients and 12.758 controls. They demonstrated that individuals with the 
MTHFR 677 TT genotype had a 16% higher odds ratio for coronary artery 
disease compared with individuals with the CC  genotype. [31]. This difference 
was statistically significant, (OR 1.16, 95% CI  1.05-1.28).  
In chapter 5 we investigated the pharmacokinetic effects of orally administered 
6[R,S] 5-MTHF versus folic acid in patients homozygous for the 677 C→T 
mutation in the MTHFR gene compared to patients with wild type gene. Our 
data demonstrate that there are no differences with respect to the 
pharmacokinetic properties of folic acid and 6[R,S]5-MTHF in relation to the 
patients’ genotype. These results suggest that the activity of MTHFR in vivo is 
not the rate-limiting step in the conversion of folic acid to 5-MTHF because the 
TT genotype did not influence the results. A remarkable finding was the high 
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levels of the non-natural 6[R] 5-MTHF isomer, one week after a single dosage 
of the racemic mixture 6[R,S] 5-MTHF. Our results suggest that the unnatural 
6[R]5-MTHF isomer is stored until it is exchanged with folic acid.  The 
biological effects of  6[R] 5-MTHF storage are however unclear. Since 6[R] 5-
MTHF is not a natural isomer it may be not beneficial that 6[R] 5-MTHF is 
stored in the body although Mader et al. demonstrated there are no serious short-
term side effects following high dosages of 6[R,S] 5-MTHF[32]. The 
bioavailabity of 6[S] 5-MTHF may be reduced due to competition with the 6[R] 
5-MTHF diastereoisomer which may have detrimental consequences when used 
as therapy in hyperhomocysteinemia.  
 
Conclusions and future perspectives: 
This thesis contributes to the concept that hyperhomocysteinemia is not just a 
consequence of atherosclerosis but is a moderate risk factor for cardiovascular 
disease.  
 
Since folic acid, in the absence of vitamin B12 deficiency, has no important side 
effects a daily therapeutic dosage of at least 1 mg seems imperative. Studies with 
clinical endpoints investigating an optimal dosage of folic acid are an important 
field for future research. 
 
The 677 C→T mutation in the MTHFR genotype is a moderate genetic risk 
factor for cardiovascular disease. Pharmacokinetic properties of orally 
administered folates are however not influenced by the genotype of the patient. 
Future research should focus on the use and safety of racemic mixtures of folates 
in patients with vascular disease. Especially the question whether the unnatural 
isomers may have detrimental effects on cardiovascular prognosis is unclear. 
 
We could demonstrate that hyperhomocysteinemia is associated with coronary 
endothelial dysfunction and that homocysteine-lowering therapy restores 
coronary endothelial function in patients with coronary artery disease. These 
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findings may have important prognostic consequences for patients with 
cardiovascular disease. Future studies, investigating the role of the endothelium, 
should reveal the pathophysiological  mechanism responsible for this increased 
risk. Especially the possible role of EDHF in hyperhomocysteinemia is, from the 
perspective of our results in chapter nine, an interesting target for future research. 
Whether folates are able to restore coronary endothelial function instantly is an 
important question since endothelial dysfunction is an important mechanism in 
acute coronary syndromes. Clinical studies are needed to reveal this question. 
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Hart-en vaatziekten zijn de belangrijkste doodsoorzaak in Nederland. Bekende 
risicofactoren als een verhoogd cholesterolgehalte in het bloed, roken, 
hypertensie en diabetes mellitus kunnen slechts een deel van het grote aantal 
patiënten, die lijden aan deze aandoeningen, verklaren. Een verhoogd plasma 
homocysteine gehalte is eveneens geassocieerd met een verhoogd 
cardiovasculair risico. 
 
Op basis van gegevens uit prospectieve en retrospectieve studies blijkt dat 
ongeveer 10 tot 20% van de Nederlandse bevolking een verhoogd plasma 
homocysteine heeft. Een verhoogd plasma homocysteine is in de meeste gevallen 
te behandelen met foliumzuur. 
 
Hoofdstuk 1 is een algemene inleiding waarin de vraagstelling van dit 
proefschrift wordt besproken. 
 
Hoofdstuk 2 : Hierin wordt de relatie vaatlijden en hyperhomocysteinemie 
besproken. 
 
Hoofdstuk 3 gaat in op het homocysteine metabolisme en de genetische basis 
die leidt tot hyperhomocysteinemie. 
 
Hoofdstuk 4 gaat in op het pathofysiologie van hyperhomocysteinemie in relatie 
tot de ontwikkeling van atherosclerose en endotheel dysfunctie. 
 
Hoofdstuk 5  beschrijft de resultaten van een onderzoek waarbij de 
farmacokinetische eigenschappen van oraal toegediend 6[R,S] 5-MTHF, de 
biologisch actieve diastereoisomeer van folaat, worden vergeleken met 
foliumzuur in patienten die homozygoot zijn voor de methyleen tetrahydrofolaat 
reductase(MTHFR) mutatie 677 C→T . De resultaten tonen aan dat 6[R,S] 5-
MTHF een ander farmacokinetisch profiel heeft dan foliumzuur met een hogere 
Samenvatting 
 146 
biologische beschikbaarheid. De resultaten zijn niet afhankelijk van het genotype 
van de patiënt. 
 
Hoofdstuk 6: In dit hoofdstuk wordt het belang van de MTHFR 677 C→T 
mutatie als risicofactor voor hart-en vaatziekten onderzocht . De prevalentie van 
deze mutatie is onderzocht in patiënten met aanwijzingen voor coronarialijden 
die deelnamen aan de regression growth evaluation study (REGRESS). De 
resultaten tonen aan dat patiënten, homozygoot voor deze mutatie, vaker 
cardiovasculaire ziekten hebben dan patienten met een normale enzym activiteit. 
(9.5% vergeleken met 8.5 %, Odds ratio 1.21 (95% C.I. 0.87-1.68)). De 
resultaten van dit onderzoek zijn echter niet statistisch significant. De meta-
analyse die verricht werd bij 2476 patiënten en 2481 controle patienten toont een 
Odds ratio van 1.22 (95% C.I.: 1.01-1.47). Daaruit blijkt dat patiënten 
homozygoot voor deze mutatie een matig  maar significant (22%) verhoogd 
risico lopen op het ontwikkelen van coronarialijden. 
 
Hoofdstuk 7: Dit hoofdstuk beschrijft de resultaten van een onderzoek naar de 
lange termijn effecten van verschillende doseringen foliumzuur met of zonder  
vitamine B12 en/of vitamine B6 op de plasma homocysteine spiegel. Bij 130 
patiënten met bekend coronarialijden die behandeld werden met 200 µg 
foliumzuur gedurende 12 weken kon een even grote reductie in het plasma 
homocysteine worden bereikt als met 1 mg foliumzuur. Het toevoegen van 
vitamine B12 had daarbij slechts gering effect terwijl vitamine B6 in het geheel 
geen effect had. De effecten die bereikt worden zijn groter naarmate de uitgangs 
plasma homocysteine spiegel hoger is. 
 
Hoofdstuk 8: In dit hoofdstuk wordt ingegaan op de effecten van homocysteine 
op de progressie van atherosclerose in de coronair vaten. Daartoe werd in de 
patiënten populatie die had deelgenomen aan het REGRESS onderzoek een 
nuchter plasma homocysteine spiegel bepaald. Met behulp van kwantitatieve 
coronair angiografie werd aan het begin van de studie en na een follow up van 
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twee jaar gekeken naar minimale obstruction diameter (MOD) en mean segment 
diameter (MSD) van de coronair vaten. Eindpunten van de studie waren de 
verandering van MOD en MSD in relatie tot de plasma homocysteine spiegel. 
Deze studie kon geen relatie aantonen tussen de mate van progressie van het 
atherosclerotisch proces en de plasma homocysteine spiegels. Ook bleek er geen 
relatie te bestaan tussen de ernst van het pre-existente coronarialijden en de 
plasma homocysteine spiegels. 
 
Hoofdstuk 9: Dit hoofdstuk beschrijft het onderzoek naar de relatie tussen 
plasma homocysteine spiegels en de functie van het endotheel in de coronair 
vaten. In dit onderzoek werd een plasma homocysteine spiegel van ≥15 µmol/l 
als abnormaal beschouwd. Coronair endotheel functie wordt uitgedrukt als een 
verandering in de coronair flow gemeten met behulp van flow doppler techniek 
en kwantitatieve coronair angiografie. Het onderzoek toont aan dat bij patienten 
met een verhoogd plasma homocysteine er sprake is van endotheel dysfunctie in 
tegenstelling tot patienten met een normaal plasma homocysteine. Belangrijk is 
dat deze resultaten onafhankelijk bleken van de foliumzuur spiegels en vitamine 
B12 spiegels. 
 
Hoofdstuk 10: Dit hoofdstuk beschrijft het effect van foliumzuur 5 mg en 
vitamine B12 400 µg gedurende 6 maanden op  coronair endotheel bij patiënten 
met een hyperhomocysteinemie. De functie van coronair endotheel werd bepaald 
met behulp van flow doppler techniek en kwantitatieve coronair angiografie bij 
de start van de studie en na 6 maanden therapie. Er was sprake van een 
significante verbetering van de functie van het coronair endotheel vergeleken 
met placebo. 
 
Hoofdstuk 11: Dit hoofdstuk beschrijft een pilot studie naar de directe effecten 
van 5-MTHF i.v. op coronair endotheel functie bij patiënten met een normaal 
plasma homocysteine. Hoewel er een verbetering kon worden gedemonstreerd 
was deze in deze kleine populatie niet significant. 
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Conclusies en aanbevelingen 
De resultaten van dit proefschrift dragen bij aan het concept dat 
hyperhomocysteinemie niet slechts de consequentie kan zijn van het 
atherosclerotisch proces maar een risicofactor voor de ontwikkeling van hart-en 
vaatziekten is. 
Dit proefschrift toont aan dat een verhoogd plasma homocysteine niet leidt tot 
een versnelling van het atherosclerotisch proces met anatomische veranderingen 
in de coronair vaten. Wel blijkt een verhoogd plasma homocysteine te leiden een 
abnormale endotheel functie in de coronair vaten. Tevens kon worden 
aangetoond dat een daling van het plasma homocysteine met behulp van 
foliumzuur en vitamine B12 bij patienten met een milde hyperhomocysteinemie 
leidt tot een verbetering van de functie van het coronair endotheel. Deze 
bevindingen kunnen belangrijke prognostische consequenties hebben voor 
patienten met een verhoogd plasma homocysteine. Of folaten een rol kunnen 
spelen bij een directe verbetering van de endotheel functie, is nog een 
belangrijke vraag waarop het antwoord niet gegeven kan worden. 
Studies die op basis van klinische eindpunten worden verricht zullen het 
definitieve antwoord moeten geven op de vraag hoe belangerijk het behandelen 
van een verhoogd plasma homocysteine is. 
 
Het mechanisme dat leidt tot endotheel dysfunctie is niet duidelijk. Toekomstige 
studies zouden het pathofysiologisch mechanisme dat leidt tot endotheel 
dysfunctie moeten ophelderen. Met name de mogelijke rol van EDHF in 
hyperhomocysteinemie is, vanuit het perspectief van de resulaten van ons 
onderzoek een interessante basis voor verder onderzoek. 
 
Omdat foliumzuur, indien er geen vitamine B12 deficiëntie is, geen belangrijke 
bijwerkingen heeft, lijkt een dosering van tenminste 1 mg foliumzuur per dag 
zinvol. Ook hier zullen studies met klinische eindpunten de vraag wat de 
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optimale dosering van foliumzuur en eventueel vitamine B12 is verder moeten 
beantwoorden. 
 
De 677 C→T mutatie in het MTHFR genotype is een milde genetische 
risicofactor voor hart-en vaatziekten. De farmacokinetische eigenschappen van 
folaten worden echter niet door het genotype van de patiënt beïnvloed. 
Toekomstige research zal zich ook moeten richten op het gebruik en veiligheid 
van racemische mengsels van folaten bij patiënten met vasculaire ziekten. 
Speciale aandacht zal moeten uitgaan naar de aanwezigheid van niet-natuurlijke 
isomeren van folaten die een mogelijk ongunstig effect bij de patiënt kunnen 
oproepen. 
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Dankwoord 
Een proefschrift afronden heeft veel weg van het zeilen op zee: Weer en wind 
bepalen de koers, soms gaat het snel soms gaat het niet en soms kom je ergens 
anders uit dan je wilde. Dat betekent toch weer de koers aanpassen, 
geconcentreerd blijven varen, zin of geen zin, met het einddoel nog lang niet in 
zicht. Al zeilend  in onbekende wateren, met een wisselende wind en stroming, 
heb je anderen nodig, op het schip en op de wal, om de reis tot een goed einde te 
brengen.  
 
Mijn drie “loodsen” , de copromotoren Henk Blom, Frits Boers en Wim 
Aengevaeren, hebben door hun kennis en doorzettingsvermogen mij zo geholpen 
dat de haven uiteindelijk toch nog vlot kon worden bereikt (letterlijk en 
figuurlijk) 
 
Als eerste wil ik Dr. Henk Blom bedanken, een van mijn beste vrienden die,  als 
copromotor, vanaf het allereerste begin een belangrijke bijdrage aan mijn 
onderzoek heeft geleverd. Beste Henk, na een jaar samen  scheikunde gestudeerd 
te hebben ben ik overgestapt naar de geneeskunde. Al snel werd mij duidelijk 
gemaakt door het “klaplopers clubje” dat geneeskunde een vak was dat je kan 
leren, maar dat de wetenschap hier niets mee van doen heeft. Dat juist jij mijn 
copromotor bent geworden, geeft aan hoe serieus je toch getracht hebt om mijn 
wetenschappelijke kant verder te ontwikkelen. We hebben vaak gesproken over 
methionine en homocysteine en het “winning team” dat de combinatie van 
klinische cardiologie en een topinstituut als het jouwe zou kunnen zijn. Mede 
dankzij jouw inzet en kennis is het resultaat, dit proefschrift, er uiteindelijk 
gekomen.  
 
Mijn dank gaat ook uit naar Dr. Frits Boers. Beste Frits, ook jij bent als 
copromotor vanaf het eerste begin bij de opzet van mijn onderzoek betrokken 
geweest. Je kennis van metabole ziekten, waaronder het homocysteine 
metabolisme, vind ik indrukwekkend. Je inzet om ook voor de zoveelste keer 
mijn stukken gedetailleerd te lezen en suggesties te doen voor verbetering heb ik 
zeer gewaardeerd.  
 
Ik ben ook veel dank verschuldigd aan Dr.Wim Aengevaeren. Beste Wim, sinds 
het begin van het onderzoek, dat de basis vormt voor dit proefschrift,  hebben wij 
samen op de catherisatiekamers gestaan om het onderzoek uit te voeren. Jouw 
doorzettingsvermogen om, ondanks de langdurige procedures, toch kwalitatief 
hoogstaande resultaten af te leveren heeft mij geïmponeerd. Ik hoop dat wij in de 
toekomst onze samenwerking verder vorm kunnen geven. 
 
Wat is een schip zonder reder?  Professor Freek Verheugt, mijn promotor heeft 
direct vanaf zijn komst naar Nijmegen de rederij overgenomen. Beste Freek, je 
zette de way points van de route vast, ik dank je voor de mogelijkheden en de 
zetjes in de goede richting op het juiste moment. 
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Een  zeilschip is moeilijk alleen te varen. De vele opstappers, sommigen voeren 
zelfs vele jaren mee, hebben het mogelijk gemaakt de haven veilig en zonder 
ongelukken te bereiken. Een aantal van hen wil ik speciaal noemen: 
 
Het personeel van de hartcatheterisatie afdeling in Nijmegen in de tijd dat ik daar 
heel veel kwam, Nort Braam, Kees Buijs, Tet Eltink, Marga Goemans,  Marga 
Harteman, Gerrie Rutten, Dorthy Schout, Hermien Swarts, Ine Verreussel, Jules 
de Wit, Fon Zeegers, Helma van Hoof en Ingrid Steinmann wil ik bedanken voor 
hun bijdrage aan het optimaal laten verlopen van de procedures die samen 
hangen met dit proefschrift.  
 
De mensen van het homocysteine laboratorium, Addy de Graaf, Maria te Poele 
en speciaal Dinny van Oppenraaij, als aanspreekpunt van het lab. Hoewel ik veel 
vroeg kreeg ik nooit de indruk dat het teveel was. Jullie inzet om alles op 
rolletjes te laten lopen heb ik zeer op prijs gesteld. 
 
Ron Rooyakkers, Helma Biemans van de CCU van het St Radboud Ziekenhuis, 
Dorotheé Ellenbroek, Ingrid Wijnen, Marjolein van Dam en Evelien de Valk van 
de polikliniek van het Hartcentrum en Femke Willems, mijn dochter. Jullie 
waren dagen geweldig in de weer met mijn studie patiënten. Dankzij jullie werd 
een sfeer van gezelligheid gecreëerd zodat de patiënten bereid waren om 
tweemaal van 7.30  ’s ochtends tot 20.30 in het ziekenhuis te blijven. Daarvoor 
bedankt. 
 
Daarnaast gaat mijn dank uit naar: 
 
Helmut Gehlmann en Hans Bos voor de instructies bij het leren PTCA’s te doen, 
toch niet zo eenvoudig als het lijkt. 
 
Wouter Jukema en  Koos Zwinderman voor het beschikbaar stellen van de data 
van REGRESS en hun hulp bij het bewerken van het manuscript. 
 
Leo Kluijtmans voor het vele werk dat hij gedaan heeft aan de MTHFR  
677 C→T mutatie en waarvan het resultaat ook in mijn proefschrift staat.  
 
Mieneke Willems, voor het zorgvuldig invoeren van vele gegevens. 
Jérémie Lefebvre, voor adviezen met betrekking tot de Engelse taal. 
 
De cardiologen, arts-assistenten, verpleegkundigen, de poli-assistentes en 
secretaresses van de afdeling cardiologie van het Universitair Medisch Centrum 
Nijmegen voor de direkte en indirekte hulp bij het verzorgen en begeleiden van 
de patiënten die aan het onderzoek deel hebben genomen. 
 
Op een verre zeereis is het goed dat er mensen aan de wal zijn die op moeilijke 
tijden het geloof in de bestemming behouden 
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De Maatschap Cardiologie Arnhem-Velp, Rogier, Loet, Rob, Pieter, Hans, 
Melvyn en Jan-Eise, voor jullie hulp en blijvend geloof in het eindresultaat. 
Eindelijk tijd voor iets anders. 
De secretaresses van de maatschap Cardiologie, voor hun zeer gewaardeerde 
hulp in de laatste fase. 
 
Mijn paranimfen, Inge van der Walle en Bart Berden die, beiden op eigen wijze, 
een belangrijke rol hebben gespeeld hebben op verschillende momenten in mijn 
leven. 
Mijn vader en moeder, af en toe moeten jullie gedacht hebben dat het nooit meer 
afkwam. 
Lucie, dit proefschrift draag ik aan jouw op, mijn zus die altijd voor mij 
klaarstaat. 
 
Tot slot, Lieve Franske, Femke, Mieneke en Iris, voor jullie was er eigenlijk te 
weinig keus, jullie moesten mee op deze tocht met alles wat dat betekent. Jullie 
zijn vast, net als ik, heel blij dat we er zijn. 
Misschien dat onze rederij  “de Droom” er nu dan toch komt? 
  154 
 
Curriculum vitae 
 
De auteur van dit proefschrift werd geboren op 21 Mei 1958 te Ede. Na het 
voltooien van het atheneum-B aan het Marnix College te Ede werd in 1977 
gestart met de studie Scheikunde aan de Katholieke Universiteit van Nijmegen.  
Na een korte periode werkzaam geweest te zijn in de weg-en waterbouw waarbij 
hij behulpzaam was bij de aanleg van een aantal kribben in de Waal bij 
Nijmegen werd in 1979 gestart met de studie Geneeskunde aan de Katholieke 
Universiteit van Nijmegen. Tussentijds was hij gedurende een klein jaar 
werkzaam in het Hôpital d’Enongal, Ebolowa te Kameroen. In 1988 werd het 
artsexamen afgelegd. Aansluitend was hij werkzaam als arts-assistent cardiologie 
niet in opleiding in het Slingeland Ziekenhuis te Doetinchem en het Academisch 
Ziekenhuis St. Radboud te Nijmegen. In 1990 werd gestart met de opleiding tot 
cardioloog (opleiders Prof. Dr. T van der Werf en Prof. Dr. F.W.A. Verheugt). 
De vooropleiding Interne Geneeskunde werd gedaan in het St. Maartens 
Gasthuis te Venlo (opleider Dr. J.J.J. Mattousch). Registratie tot cardioloog 
volgde op 1 december 1996. Daarna was hij werkzaam als tijdelijk staflid op de 
afdeling Cardiologie van het Hartcentrum te Nijmegen (Hoofd Prof. Dr. FWA 
Verheugt). In deze periode werd tevens gestart met het onderzoek dat de basis 
vormt voor dit proefschrift. Vanaf 1 mei 1998 is hij werkzaam als cardioloog in 
de maatschap Cardiologie te Arnhem-Velp.  
Hij is gehuwd met Franske van Duuren en heeft drie dochters, Femke, Mieneke 
en Iris. 
 
 
 
 
 
 
 
 
 
